b e h r n g e r n g e l h e value partnershipc n e n trust patients able rely receiving best possible therapies medicines enquired back life partnerships important successfully regain confidence boehringer ingelheim body stroke progress space partnerships play major role boehringer even balance security space ingelheims research development best basis good ideas benefit patients open ideas powered people innovation also calls strong scientific partners two hr managers discuss limits indi viduality diversity exploring new horizons together stronger research development cooperations contribute success working together combat counterfeiting pharmaceutical companies counterfeit medicines success tradition space special corporate culture imprint learning science fiction looking future beyond medication longterm partnerships benefit patients pharmaceutical companies payer organisations work together long term partners passion animal health boehringer ingelheims new animal health business looks likevalue h r u g h p r n e r h p today researchdriven pharmaceutical company boehringer ingelheim focuses ever variety partnerships intensive networking within company thereby important exchange cooperation external partners boehringer ingelheim one worlds leading pharmaceutical companies headquartered ingelheim germany boehringer ingelheim operates globally currently total employees focus familyowned company founded researching developing manufacturing market ing new medications high therapeutic benefit people animals embracing social responsibility important element boehringer ingelheims corporate culture includes worldwide commitment social projects making health initiative well paying close attention employees respect equal opportunity reconciling career private life form founda tion togetherness company also focuses environmental protection sustainability everything boehringer ingelheim achieved net sales billion euros rd expenditure corresponds per cent net sales enquired w h p r n e r h p r e p r n f r b e h r n g e r n g e l h e boehringer ingelheim today partnerships important ever asked chairman shareholders committee members board managing directors value partnerships company contribute success enquired establishment scien tific department cooperation heinrich wieland cooperations pfizer novo geigy around aim building international business two important historic examples partnerships partnerships continue play sig nificant role future efforts offer customers measurable affordable acting therapeutic progress beyond purely innovative medicines together innovative companies act together find solutions time remain independent family finding owned company solutions christian boehringer chairman shareholders committee enquired n animal health business partnerships become vital success many key dimensions supply additional services improving customers order provide value beyond product regarding rd ability work together several external partners develop innovative tech nologies research approaches innovate many ideas products solutions indepth possible diverse teams com compete bining different skills capabilities standing worldwide building global hubs intensified cooperation therefore part hubertus von baumbach customers animal health strategy chairman board managing directors vastly accelerated inte gration merial needs allan hillgrove p member board managing artnering helps us developing directors responsibility strengthen capabilities human pharma serve customers better innovative partners allow us improve ability innovate ability technologies compete look beyond see partnerships central horizon partnering decisive build future success boehringer ing strong relations customers research ingelheim partnerships better understanding needs require firstly indepth allowing improve results approaches understanding customers needs hence bringing health patients meeting needs mutually beneficial way future partner dr joachim hasenmaier ships likely include cooperating member board managing payers reimbursement bodies directors responsibility define value products animal health society paid delivery value partnerships also involve gaining expertise outside company employing competitive responsive enquired p artnerships key success company think partnerships think partnerships internally well externally together levels within outside organi sation think partnerships achieving customers patients stakeholders employees work together collaborate foster inclusive optimised culture drive diverse thinking innovation organisation results true partnership team striving partner goal team another way saying together everyone simone menne choice achieves member board managing directors responsibility external finance p artnership means supporting driving innovators sharing knowledge combining strengths diverse dr michel pairet finance division member board managing apply external partners thinking directors responsibility internal business partners innovation particular together innovation overcome challenges major projects p thereby achieve optimised results artnerships key inno dr andreas neumann vation discoveries member board managing made individuals acting directors responsibility usually begin human resources single persons idea tested experimentally discussions exchange creative minds internally externally developed true solution aspiration boehringer ingelheim partner choice external innovators establishing creative cooperative environment bringing together scientists diverse back grounds key ambition breakthrough innovation valued patients families society p r g r e h r u g h p r n e r h p boehringer ingelheim researchdriven pharmaceutical company progress essential sustained success partnerships play increasingly important role external researchers health insurers least patients progress boehringer ingelheim first foremost means helping people animals innovative medicines worldwide p r g r e h r u g h p r n e r h p progress partnership p e n e developing new medicines calls power innovate strong scientific partners boehringer ingelheims new research strategy backing open innovation interaction external specialists inspiring research openness means recruiting outstanding scientists progress partnership dr clive r wood open innovation best sense boehringer ingelheim understands looking medicines future says wood corporate senior vice open best new ideas president human pharma concepts inspire research discovery research development wherever working boehringer emerge heading eyes ingelheim since open precisely innovation happens internally exter nally way building perhaps even reversed one ideal cradle innovation core causes disease experts weill cornell one hand contribute profound understanding chronic pulmonary diseases extensive experience lung research team front line boehringer ingelheim hand particular expertise new research comes discovering developing new respiratory therapies complement hortness breath perfectly excellent fields emerge persistent cough combination enables us rapidly usually translate new scientific findings first signs chronic pharmaceutical research develop obstructive pulmonary disease copd ment says dr clive r wood boehringer ingelheim truly widespread disease great corporate senior vice president disco reshaped discovery research strategy number people age research wood essentially research new medicines since affected high risk estimated companys head research divided four research areas million people worldwide suffer human pharma immunology respiratory diseases disease thus prevalent scientists academic cardiometabolic diseases oncology diabetes experts estimate research company share diseases central nervous system every third fatality attribut passion new discoveries work ability modulate bodys able copd disease incurable together translate new immune system opened new exciting treatments improve medicines says wood explaining ways treat cancer consequently symptoms thereby counter partnerships like promising discovery research organisation dangerous downward spiral increasing researcher grew stud boehringer ingelheim plans ailments physical inactivity ied uk spent majority increase investment oncology help patients researchers career usa work additional research therapeutic boehringer ingelheim weill cornells ing boehringer ingelheims headquar area focused immunooncology department genetic medicine ters ingelheim germany since boehringer ingelheim also estab usa breaking completely new front line new lished overarching scientific platforms ground together conducting research fields emerge constantly immune modulation focus research deterioration engaged intensive interactions expertise resources areas cutting small airways stopped external experts across multiple therapeutic areas progress partnership biberach germany ridgefield ct usa vienna austria kobe japan boehringer ingelheims major global research development sites human pharmaceuticals research beyond borders ofthe art capabilities protein bio possible alone companys company also established pro therapeutics delivering researchers published several hundred gramme explore emerging scientific onequarter new candidates scientific articles many prestigious approaches technologies collab early pipeline says wood journals wood proud large oration external partners number believes key perfor within beyond core research mance indicator innovation therapeutic areas also important recruiting next boehringer ingelheim committed generations talented scientists time right developing next generations company today best young pioneering medicines goal minds attracted publications get improving lives patients high top journals find places medical need new insights great science brings new medi pathways drive diseases critically fully involved cines patients important identify breakthrough research beyond borders serves medicines future says wood radar next big wave innovation creativity commitment open innovation requires active collaborating external research insights centrally important twoway communication external institutions boehringer ingelheim drughunting spirit world explains whilst must ensures scientists keep new drug target ensure appropriate protection fingers pulse miss identified researchers decide best innovations enormous new research methods approach therapeutic purposes amount work shared emerging connected history developed wood believes external engage best partners longterm partnerships exceptional abilities discovering ment participation greater universities kyoto univer developing small molecule drugs scientific community essential create sity japan harvard us see contributed leading pipeline expand connections facilitate heart research successes sure continue path future opportunities beyond borders critical core driver future convinced scientific publications boehringer ingelheim also active success however large molecule drugs crucial communication among public private partnerships also required address significant researchers encourages col structural genomics consortium range therapeutic targets leagues boehringer ingelheim seeking solutions difficult recent years developed state publish many findings medical problems crowdsourcing progress partnership projects way keep boehringer ingelheims eye topics still early research development conceptual stage wood continues time right ready get fully involved since immune modulation example scientific platform approach boehringer ingelheim immune system common denominator boehringer ingelheim com many diseases across wide variety mitted research development medical areas wood explains previ ously company would employ immunologists relevant therapeutic area teams weve brought together single unit instead around specialists sational units immune modulation carrying research identify novel underlying mechanisms drive possibilities influencing immune billion euros fibrosis examples scientific platform system immune pathway must research development approaches boehringer ingelheim expenditure turned disease auto currently exploring however wood immunity excessive colleagues already discuss activation immune system may ing areas regenerative medi pathway must cine one possibility turned fight cancer new culture openness may insufficient activation mutually beneficial partnership immune system creates enormous research guides companys value scientists work together people research development wood states common problems worked research mentions ofev outstanding opposed working different organi development example company one medicines making strong contribution sales growth tyrosine kinase inhibitor nintedanib boehringer ingelheims oncology research division originally developed highly effective lung cancer medicine two talented scientists biberach site germany hit upon idea mechanisms drive cancer might also effective idiopathic lung fibrosis says course implied active ingredient nintedanib could used treating disease demon strated potential series experiments successfully argued testing nintedanib additional indication importance common disease mechanisms shown important open mind ambition help patients heart drug discovery boehringer ingelheim reshaped discovery research strategy progress partnership e x p l r n g n e w h r z n g e h e r w e r e r n g e r transforming bright scientific ideas new medicines patients need requires staying powerand increasingly also strong international network partners boehringer ingelheim continually seeking strong partners world pursue new paths drug discovery progress partnership oncolytic viruses among promising therapeutic crossing boundaries approaches cancer research boehringer ingelheim launched new strategy global research organisa innovation partnerships tion combines focus companys boston strengths increased use internal synergies bold commitment external boehringer ingelheim office boston innovation research beyond borders usa goal expanding network initiative represents new approach scientists organisations example aim explore novel scientific approaches boehringer ingelheim working scien innovative technologies within beyond tists harvard stem cell institutes boehringer ingelheims core therapeutic areas fibrosis network order study new treat could future focus areas company ment options fibrotic diseases life science research asia rapidly fibrosis characterised patholog growing importance offering significant ical proliferation fibrous connective tissue new opportunities pharmaceutical discov organs boehringer ingelheim ery research particular areas focus harvard university scientists carry regenerative medicine one areas collaboration research diseases idiopathic pul excellence threeyear partnership combat cancer monary fibrosis chronic kidney failure kyoto university japan way nonalcoholic steatohepatitis look together scientists boehringer ingelheim goal boehringer ingelheims cancer pathophysiological mechanisms kyoto university investigate novel thera research develop new therapies imp rove root fibrosis could prove peutic approaches restore hearing ability patients lives achieve company gamechanging treating fibrotic diseases people disabling hearing loss continues expand network partner advantages partnership million people live severe condi ships academic institutions biotech researchers able pursue tion million children due nology companies relationships focus work much greater depth worldwide aging population dramatic early emerging science technology leverage synergies share resources increase frequency condition aimed true breakthroughs therapy efficiently expected hearing loss increases age needs patients caregivers well effective treatment could healthcare system requirements guide restore hearing loss sufferers rely researchers hearing aids one example strategic partner joint research team pursues new ship viratherapeutics biotech com hair cells inner ear idea aiming understand mechanisms pany located innsbruck austria regeneration damaged hair cells investigates virusbased immunotherapeu inner ear hearingimpaired people tics cancer treatment april sensory cells longer work properly boehringer ingelheim venture fund became new therapeutic approaches intended lead investor viratherapeutics restore overcoming limitations oncolytic viruses among prom hearing aids ising emer ging therapeutic approaches boehringer ingelheim opened office cancer research together two companies september kyoto universitys med pursued earlystage research examining ical innovation center establish col cancerdestroying oncolytic viruses since laborations scientists japan september broaden boehringer ingelheims oncolytic viruses act infecting research field hearing loss destroying cancer cells process also leads research beyond borders team recently release tumor antigens launched another partnership china normally hidden immune system southeast university nanjing bodys cells socalled situ vaccina focus complementary approaches tion effect triggers sustained response restoring hearing ability adaptive immune system tumour cells pprrooggrreessss tthhrroouugghh ppaarrttnneerrsshhiipp guest contribution l e r n n g f r c e n c e basis several different trends identified highly likely become reality next years f c n trend self aware patients patients selfimage already evolving healthcare set undergo revolutionary changes however undergo even years time pills produced printer part radical transformation everyday life like virtualreality applications hospitals patients selfaware crit ical doctors pharmaceutical healthcare companies must prepare new era becoming manufacturers tell used patients partners intent informing prophylactically well diseases diagnosed possible treat ments internet enables patients achieve level knowledge approaching doctors invest enough time ever patients future insist playing nyone interested first sight healthcare sector active role deciding hap future holds read science facing era change real tsuna mi pens companies fiction stories watch science approaching full impact healthcare sector doctors fiction films future felt years many different means adapting fact patients turn quite like star trek examples give idea severe demand treated partners movie ex machina stories serve changes today paralysed valuable source inspiration people able walk thanks trend us science fiction glue binds exoskeleton printers enable victory parade today tomorrow helps us customfit casts splints individual sensors exponential thinking need make patients plans drones meaningful assumptions deliver defibrillators emergency sensors measure assess future likely bring linear think patients doctor unable get vital functions many people ing simply extrapolates current time would spread rapidly next years developments future considered science fiction years socalled electronic tattoos already take us forward already evident ago today reality available market continu glance many industries inspired ously measure body temperature undergone radical changes science fiction familiar current pulse rate blood pressure per past years due trends healthcare information son whose skin tattoo attached internet retail media technology think exponentially sensors might soon installed bath pprrooggrreessss tthhrroouugghh ppaarrttnneerrsshhiipp rooms peoples homes could trend instance analyse peoples urine every augmented day offers many new opportunities virtual reality health insurers example people follow healthconscious lifestyle could offered discounts moreover augmented reality every increasing numbers people seeking bodys lips many months due optimise health pokmon go smartphone game example record number future everyday occurrence deep sleep periods healthcare industry night adjust daytime behaviour various possible applications augmen achieve better recovery bertalan mesk ted reality enable doctors partici nighttime pate operations even perform md phd remotely data glasses enable significantly effective sha trend red training junior medics printing possible past virtual dissecting room opera even cancer medications fre tion performed local anaesthetic also known quently produced customised basis patients wear data glasses medical futurist individual patient future show pictures home approach followed feel ease despite unfa amazon top many medicines doctor miliar environment author keynote speaker determined right combination researcher active ingredients send data conclusion presentations eg courses pharmacy use printer harvard stanford produce customised pills pati radical changes one yale universities singularity ent concerned initial trials using thing common first glance universitys futuremed course method already successfully appear consequences nasa ames campus completed show pills technological revolution yet actual organisations including even break particularly quickly fact reflect cultural revolution ten biggest pharmaceutical patients body soon printers sense people companies one longer used manufacture heart things especially pills also instance produce top voices globally health true patients enjoy part entire body parts patients care technology dr mesk nership equals protagonists receive transplants featured dozens top healthcare needs wishes publishers including cnn shape development national geographic forbes healthcare sector never trend time magazine bbc healthcare companies must adapt virtual testing new york times keep rapid new active changes ideally help push ingredients forward must welcome new opportunities currently pharmaceutical research com information technology affords panies conduct laborious testing without involvement actual must ensure new ideas imple series trials order test new active patients advantage mented quickly must urge reg ingredients process takes many computers could test thousands differ ulatory authorities make rapid years requires participation ent combinations active ingredients pragmatic decisions large number patients often within short space time must transform selfimage exposed certain degree risk identify best ones would save even big company future might soon thing past pharmaceutical manufacturers lot increasingly less capable safeguard ever thanks computers able time bring new medicines onto ing success achieve process large amounts data experts market much faster past require network many call big data future new active may even soon possible use artificial partners first foremost among ingredients might thus undergo virtual intelligence testing active ingredients patients progress partnership l n g e r p r n e r h p b e n e f p e n partnerships increasingly gaining importance throughout boehringer ingelheim professor dr dorothee bartels spent last months travelling around usa behalf company order forge close contacts doctors healthcare organisations insurers epidemiologists conclusion nowadays cooperation begin much earlier couple years ago objective build genuine trustful longterm partnerships progress partnership prof dr dorothee bartels prof bartels exactly different today global head epide quently already long ordeal prof bartels previously phar miology boehringer ingelheim right medicine found maceutical company talked since holds masters patients great strain health insurers pharmacists shortly degree epidemiology possibly even lifethreatening launch medicine harvard school public health also expensive health insurer mainly commercial issues usa doctorate hanover today seek jointly characterise patient pricing today trustful partnerships start medical school germany groups early able offer diseaserelated discussions rather professor epidemiology individual therapies analysis data productrelated discussions way public health routine clinical practice comes play optimally pursue common goal adjunct professor mcgill data already available prior partners helping sick people per university canada since approval example electronic med sonalised medicines ical records claims data used identify characterise patients practical terms pharmaceutical unmet medical need launch companies notice change prof bartels today health insurers longer wish purpose example weve licensed analyti pay per visit doctor per prescription medicines cal platform humana fifthlargest health plan increasingly criterion rather quality whether usa able work jointly humanas patient data treatment successful relationship pharma well databases licensed boehringer ingelheim ceutical companies means instead pure volumes without breach data protection increases data thats say discounts insurers negotiating reim pool helps search suitable patient subgroups bursements depend effectiveness safety enables close partnershipbased cooperation within medicine routine clinical use socalled valuebased framework evidence based medicine contracts therefore gaining ground paradigm shift volume value model pharmaceutical company going solo way role personalised medicine play prof bartels prefer put way general going prof bartels critical one nowadays question solo longer expedient neither pharmaceutical companies much medicine best help health insurers pharmacists providers patients organi individual patient thats also main reason coopera sations able improve humans health tion health insurers pharmaceutical companies achieve progress possible joint effort must today begin much earlier patients fre trustful longterm partnershipbased cooperation progress partnership p n f r n l h e l h january saw union sanofis animal health business merial combined boehringer ingelheim animal health business unit worlds second largest animal health operation employees products available markets global presence countries progress partnership leader vaccines anti boehringer ingelheim parasitics continue special animal health focus prevention addressing spectrum treatment needs aim develop new effective medicines diagnostics diseases high unmet medical needs continue invest existing marketleading positions swine equine pets pets expanding offering cattle poultry livestock swine increased exper tise resources offer custom ers innovation wider set dr joachim products services want sup hasenmaier member equine board managing directors port farmers raise care ani responsibility mals healthy sustainable animal health financially viable way builds con fidence consumers know combined strength boehringer ingelheims animals sanofis animal health organi sations improve com healthy petitiveness animal health busi ness strategically important humans company complementary portfo global player lios make two businesses perfect healthy fit together serve customers partners even better offering broader range health solutions committed helping com products available countries continuing excellent panion animals live longer better service delivery customers expect owners today lifelong combined animal health emotional connections pets team committed using combined consider family members scale resources deep rd capabili familyowned business take ties lead industry improving longterm perspective achieve countries animal wellbeing welcoming merial benefit employees boehringer ingelheim family reflects customers passion animal health com boehringer ingelheim committed share mitment making industry even ensuring smooth transition poultry better improving human ani business continuity organisations swine pets mal health combined two integrate deeply experienced new leading industry players common leadership team drawn vision recognise critical boehringer ingelheim merial back livestock importance serving animal health grounds steer business units companion animals needs globally focus preven strategy bear commitment tion know animals customer partner relationships cattle healthy humans healthy innovation beyond equine p r n e r h p b e n r u patients able trust doctors pharmaceutical companies together ensuring provided best possible therapies well effective safe medicines boehringer ingelheim striven maintain trust years p r n e r h p b e n r u partnership based trust partnership based trust b c k l f e age anna higgs suffered serious stroke paralysed one side body british woman struggled physical psychological effects many years knows path back life easier right partners side nna higgs looking forward nice christmas celebrated christmas day whole family fathers house harlow north london annas newborn son henry one month old also suddenly anna didnt feel well difficulty speaking also walking family took home put bed following morning annas sister noticed something seriously wrong called emergency doctor devas tating diagnosis stroke age partnership based trust point one nurses told id probably need electric wheelchair left hospital totally knocked young mother transferred local hospital harlow two weeks later received physio therapy every day initially concen trated right leg since wanted anna higgs home harlow learn walk quickly pos sible progress slow anna repeatedly suffered bitter setbacks local hospital harlow contracting hospital infection skeleton staff christmas weakened meant possible per point one nurses told id form magnetic resonance imaging mri probably need electric wheelchair scan anna therefore trans left hospital anna remembers ferred another hospital away totally knocked emergency treatment initial spent six months hospital tests even though husband craig afterwards could go back parents relatives visited old flat third floor every day anna became increasingly local authority found flat desperate could longer move ground floor start par right arm right leg ticularly difficult period anna longer sight right eye learn cope everyday life really worried says anna despite paralysis ex understood happened tremely difficult small child greater fear looked says use left hand though entire life hitherto everything including changing henrys would liked looked nappies although family young son could support anna felt possible annas husband craig hospital choice give job order people looked everything stay home clear times partnership based trust struggle control leg today anna walk normally partnership based trust despite difficult situation able get lot done organise things cant use jokes anna fought helping angels way back life despite physical limitations took dancing years ago organises annual dance cabaret show aid self help group stroke victims support family relationship hus treatments physiotherapy band craig helped anna escape almost immediately left hospital deep hole fallen communication broke com stroke however way pletely one moment next back contented independent anna cope everything life would much easier able rely strokes rise around globe complete mental breakdown professional partners leave past years followed two years young hospital serious stroke significant increase number woman longer left house urgently need safety net fall patients alone million given hope says says need doctors people worldwide affected many seriously worried id another carers therapists talk one patients lack access specialised stroke precisely happened another discuss things follow hospital therefore receive second stroke less severe joint plan anna knows well optimum treatment care experts first one experience patients estimate roughly every minutes turning point came hardly capable dealing things stroke patient could anna decided take antidepressant situations saved specialised hospital either things slowly improved looking back anna actually dies suffers serious complications deep despair faded back thinks lucky compared boehringer ingelheim helping ground anna found strength others despite bad experience change situation comp anys fight iron discipline worked young definitely got angels initiative works leading regain control right leg help attention older organisations experts improve son helped says wanted patients true doctors access specialist stroke hospitals able treat like therapists also friends around world initiative aims mother treated child recently friends raised build community least motivated struggle buy anna device helps new stroke centres special control leg today anna strengthen muscles right leg ised hospitals europe walk normally contrast using electrical impulses alone end initiative physiotherapy right arm still anna knows fact training nurses carers stroke disappointing hardly move regained life specialists offers simulationbased day point gave enjoy great extent due training equips hospitals used strength despite difficult situation stroke boxes keeping yearold says years ago able get lot done organ motto angels initiative right arm tattooed ise things fortunately giving life chance way least looks nice even im open direct person partnership based trust case stroke fast balance eyes face loss balance blurred vision one side face stroke headache drooping dizziness arms speech time arm leg weakness speech difficulty time call ambulance time brain immediately stroke disruption brain function hours due insufficient supply brain region oxygen facts stroke clot retrieval treatment increases chance good outcome stroke treatable clogged blood vessel stroke complex medical issue per cent cases blood vessel ways significantly clogged clot embolus calcifi reduce impact cation arteriosclerosis cause recognizing signs stroke early treating medical emergency admission million specialised stroke unit strokes per year access best worldwide professional care substantially improve outcomes million oxygen cause disability function affected brain area temporarily permanently source wwwworldstrokecampaignorg impaired partnership based trust w r k n g g e h e r c b c u n e r f e n g monitoring traceability medicines particular importance boehringer ingelheim counterfeit products endanger health patients company works together retailers manufacturers make medicines secure counterfeiting boehringer ingelheim also gives high priority pursuing suspected cases c omplaints resulting effect experienced responsible protection coun suspicions counterfeiting unexpected side effects short terfeiting boehringer ingelheim occur suspicion someone may products sent times year doctor pharma provided doctors patients forwarded facility manufac cist hospital patient contacts one counterfeit medicine tures corresponding original boehringer ingelheims national subsid order us able inves boehringer ingelheim colleagues iaries say packagings tigate cases ask suspi compare packaging tablets look different usual ones cious products sent us retention samples submit batch number expiry date details able come reliable con products chemical analysis says packaging match clusion cases photos already schn per cent cases details blister packs bot provide initial indications counterfeit suspicion turns unfounded tle label possibly expected ing explains johannes schn however something amiss partnership based trust range manipulation launched securpharm initiative expiry date packaging securpharm developed sys complete counterfeiting products securpharm works tem unique labelling medicine alien ingredients luckily product packaging data matrix code familiar portfolio isnt badly affected train tickets example contains counterfeiting manu encrypted information manu facturers says schn facturer medicine batch counterfeiters focus antimalari number expiry date infor als antibiotics lifestyle products mation stored central database medicines treat erectile dys soon pharmacist scans pack function dieting aids hair restorers prior selling system checks counterfeit medicines represent whether data valid records growing problem least sale product means internet makes easy criminals one sell pack twice trade counterfeits operation explains schn pharmacist pangea coordinated every recognises pack incorrect code scan code year interpol seized five immediately times many counterfeit drugs pharmacist scans pack prior selling prohibited medicines enormous lead almost ten times value securpharm system tested frequently tablets solutions contain around pharmacies germany active ingredient sometimes since january products actually contain active boehringer ingelheim feature ingredient much lower concen code pipeline trations worse eu directive makes many criminals also use toxic kinds anticounterfeit systems man substances manufacture counterfeits datory already enormous lead says schn com supply chain security pany also takes part anticounterfeit boehringer ingelheim invol initiatives outside germany enabling ved combating counterfeit medicines example detailed tracking deli years inter parcels pallets special seals database departmental work johannes schn designed prevent packs system checks whether data valid colleagues also primarily opened unnoticed prior sale records sale product undertaking outset whole boehringer ingelheim also puts range measures make supply emphasis providing information chain medicines secure instance patients also detect coun company campaigned intensively terfeits keep number typical implementation new coun warning signs mind seller terfeit protection directive euro trustworthy offer really pean union eu european good true pack look federation pharmaceutical industries information tampered associations efpia directive spelling mistakes text pharmacist recognises original pack due implemented across europe tablets capsules differ immediately february precise usual colour form medicine actu regulations drawn eu ally tastes smells different usual politicians boehringer ingelheim patients make sure ask already started implementation pharmacist contact manu new regulations piloting facturer directly even germany sweden absence effect medicine partnership major com produces unusual side effects counter petitor representatives feiters keep trying says schn pharmaceutical wholesale pharma together make hard cists associations boehringer ingelheim possible p r n e r n e e p c e even balance security space best basis good ideas benefit patients principle crucial boehringer ingelheims corporate culture reflected respectful way employees important partners inhouse treated also companys social commitment improved health worldwide partners need space p w e r e b u r p e p l e partners need space maria tereno global head diversity inclusion discusses boehringer ingelheims corporate culture colleague shawn liu global head human resources hr strategy transformation takes motivate top young talent role leaders play limits individuality diversity everything perfect thinking ensures pipeline always filled tereno mr liu tereno laughs well good ideas ultimately also employees great corporate culture whats deci leads market share growth crucial success sive current success liu diversity society work boehringer ingelheim continue successful force simply fact tereno quite simply coming years company oper ignored respond diversity company always driven ates worldwide boehringer ingelheim need embrace inclusion culture capacity innovation pharmaceu highly diverse workforce weve without inclusion diversity doesnt tical industry increasingly competi people wide range nationalities contribute much worst tive business important organisation different case may even lead chaos ever remain innovative long cultural backgrounds every age need working environment values term basis thats possible group different experiences partnership diversity thought dedicated motivated employees leverage diversity drive colleagues trust one another liu true successful companies focus innovation business growth dont need watch everything particularly people taking say wellbeing engagement mean tereno exactly diversity mix seriously proud tereno strong diverse teams inclusion making mix work part company important resource everybody needs feel valued long time across businesses mat particular generate good ideas require inclusive leadership culture ter whether human pharma animal studies show many companies dis leaders provide honest con health across countries matter courage difference workforce structive feedback recognition whether europe america asia around per cent marketable achievements simple employees heart ideas left table mainly due thank great work company worldwide lack endorsement diversity partners need space must learn enable diverse employees achieve best perfor mance liu leads another important ambitions company must different personal family back topic moments matter learn enable diverse employees grounds make best contribu boehringer ingelheim employees achieve best performance tion company simple examples numerous interactions company naturally wouldnt realistic cre place germany childcare colleagues within com ate individualised approaches flexible working hours another possi pany supervisor employee perfor employees cus bility could allowing time spe mance feedback one obvious example tomised employee experience aim cial innovation labs people organisation need identify look different needs different meet order work together creatively critical moments matter groups employees create tailored projects way one employees deal extremely approaches group key projects development well respond diversity works performs best global diversity inclusion office workforce need provide custom ised employee experience lets talk inclusion lets turn one challenges moments matter successfully establish todays hr work boehringer ingelheim chance engage inclusive culture finding enough young talent everyone organisation tereno first leaders teams need company excellent best consciously demonstrate inclusive reputation behaviours aiming foster innovative liu true however alone mean precisely ideas secondly organisation needs enough unfortunately tereno people work different continuously create right frame war talent accept ways driven different goals work infrastructure people genuine talents able partners need space choose ideal employer cant simply sit back recruit employees traditional way instead need think sell jobs opportunities talented people increasingly important particularly paradigm emerging markets achieve shift need underline offering working environment values maria tereno diversity challenging interest giving people equal access benefits ing roles development career tailored choices different people opportunities fact different needs different expectations treat employees charge respect boehringer ingelheims one size fits best employer awards global diversity boehringer ingelheim regularly picks inclusion office since must surely help march liu theyre certainly helpful particu larly branding perspective brazilian birth ever dont see brand japanese portuguese thing actually accumulation roots master many good efforts treat employees business administration well boehringer ingelheim like university aspects ive mentioned toronto joined boehringer ingelheim gender diversity female brazil roles leadership cluded brand management customisation tereno first diversity head marketing gender although however various products globally gender visible diversity locally october dimension leveraged appointed regional increase gender balance lead business head human ership reflect diverse markets pharma japan aus customers per cent tralia role healthcare decisions family part team devel taken women weve great female oped people strategy leadership talents need continue one com foster development panys core priorities important develop female talent pipeline another diversity opportunity leveraging different generations ranging baby boomers around age fit enormous amount knowledge experience millennials around age developing career potential talent future partners need space diversity minority individual compliance ethics balance team innovation composition growth diversity mix diversity also inclusion making mix work limits diversity liu also company values big challenges surely everyone get well give cir hr strategy whatever want cumstances weve colleagues liu primarily concentrating tereno course many different countries many strategically areas would produce chaos shawn different nationalities treat cul actually create competitive advan previously mentioned first every tural background age gender etc tage boehringer ingelheim effective one understand strive equally dont room leadership customised employee expe achieving goals everyone anyone opposes values rience diverse inclusive accept need results respect trust empathy passion organisation time need lastly need make sure tereno aim set good example run hr like business dayto colleagues enjoy working together human resources team day activities similar teams liu laughs exactly companies staff records recruitment meetings involve passionate debates staff name always benefit exchanges customer satisfaction continuous improvement professionalism partners need space concentrating areas actually create competitive adv antage shawn liu global head hr strategy transformation boehringer ingelheim since january chinese manager held several leadership roles boehringer ingelheim country corporate level previously worked several consulting industrial fortune organisations boehringer ingelheim six years new role works colleagues achieve greater effectiveness thank one last question liu five years time id really like efficiency work hr would like achieved see boehringer ingelheim become true secure strategic five years time pioneer innovator busi role company tereno hope five years ness also people management time boehringer ingelheim continues long keep marching competitive today effectiveness efficiency fronts need best talents leveraging diver human resource management well sity inclusion one way attract get retain ppaarrttnneerrss nneeeedd ssppaaccee u c c e f r r n history boehringer ingelheim history shaped longterm strong successful partnerships first days social interaction important founder company inter action based respectful trusting cooperation within company outside partners marked corporate culture puts people first partnerships arise people ready assist one another help one another order mutually progress time also important create neces sary space personal development boehringer ingelheim worked according principle years christian boehringer chairman shareholders committee ppaarrttnneerrss nneeeedd ssppaaccee space health according world health organisation per cent mexicos rural population mainly rely wood fuel heating cooking burning wood produces large quantities harmful substances small soot particles directly enter lungs houses poorly ventilated soot concentration exceeds one hundred times level threat health constantly breath ing soot particles indoors result diseases affected mainly women children example copd asthma lung cancer together fondo para la paz charity boehringer ingelheim mexico set goal improving quality life patients respiratory diseases also tackling causes end boehringer ingelheim since installed ecological stoves poorer communities mexico enormously improving lives people project also reduces greenhouse gases delivers improved carbon footprint partners need space space culture ernst boehringer established international days ingelheim germany order provide insight life culture nations peoples since annual series cultural events guided visitors history around globe greek antiquity modern era partners need space space patient emp owerment boehringer ingelheim employees usa long served volunteers local americares free clinic people without health insurance boehringer ingelheim cares foundation americares launched new health coach programme grew com munity conversations unmet needs health coaches speak span ish english work oneonone patients chronic diseases high blood pressure high cholesterol diabetes help develop action plans reach health goals space togetherness every year people disability boehringer ingelheim employees cele brate togetherness festival companys biberach site germany come together get know one another exchange views learn ten years boehringer ingelheim part nering local social organisation people disability biberach employees since worked volunteers various projects partners need space space good ideas use open source technology manufacture electronically controlled artificial limbs low cost funmove team south korea took first place good idea making health changemaker competition background project south korea artificial limbs generally much expensive relation average income level boehringer ingelheim launched competition together charitable organisation ashoka partners need space space creativity since boehringer ingelheim supported people disability paint behinderte menschen malen project initiated state office social affairs young people care mainz germany one highlight annual exhibition companys staff restaurant ingelheim people disability present paintings partners need space space family already first world war boehringer ingelheim began building flats houses near plant site ingelheim germany employees families partners need space space team spirit occasion companys th anniversary photomontage companys employees made picture present workforce albert boehringer hung many years desk space rest relaxation one first companies germany boehringer ingelheim introduced paid holidays employees space ideals september albert junior older son companys founder wrote letter brother ernst still school time among things advised younger brother dont per ceive ideals solely making money also common good example industrialist practice social wel fare among workers imprint f u h v e n q u e r e r c e n p l e e n h e e c n c u boehringer ingelheim gmbh binger strae ingelheim germany telephone fax contact corporate division communications public affairs email pressboehringeringelheimcom internet wwwboehringeringelheimcom issued boehringer ingelheim gmbh concept design layout mpm corporate communication solutions mainz wwwmpmde photos illustrations boehringer ingelheim cover adobe stock tim wegner rainer mirau getty images shutterstock top science photo library bottom plainpicture stewart turkington dieth schrder fotografie fondo para la paz iap alex ostasiewicz americares top st elisabeth stiftungheggbacher wohnverbund bottom sabine haase left top german siedler left bottom susanne herbst right andreas secci bottom printed neue sddeutsche verlagsdruckerei gmbh ulm copyright boehringer ingelheim gmbh rights reserved part annual report may reproduced transmitted form means electronic photocopy without permission writing boehringer ingelheim gmbh figures third parties used annual report based data availa ble time financial statement drawn wwwboehringeringelheimcom annualreportboehringeringelheimcomb e h r n g e r n g e l h e annual report value innovationf na n ci l h ig h li g h ts u mm ry r ep r amounts millions eur unless otherwise indicated change net sales region europe americas summary asia australia africa business report prescription medicines consumer health care animal health biopharmaceuticals industrial customers sales research development personnel expenses average number employees operating income operating income net sales group profit net sales group equity return group equity cash flow investments tangible assets depreciation tangible assets top products prescription medicines top products consumer health care net sales millions eur change net sales millions eur change spiriva dulcolax pradaxa buscopan trajenta jentadueto pharmaton micardis mucosolvan v e r v e w company shareholders perspective key aspects group management report consolidated financial statements product portfolio u r c p n boehringer ingelheim group one worlds leading pharmaceutical companies headquartered ingelheim germany boehringer ingelheim operates globally affiliates total employees focus familyowned company founded researching developing manu facturing marketing new medications high therapeutic value human veterinary medicine social responsibility important element corporate culture boehringer ingelheim includes worldwide involvement social projects initiative making health caring employees respect equal opportunities reconciliation work family life form foundation mutual cooperation every thing company focuses environmental protection sustainability c n e n company product portfolio shareholders perspective prescription medicines key aspects respiratory diseases corporate bodies cardiovascular metabolic diseases oncology group diseases central nervous system management report infectious diseases information group report economic position animal health risk report livestock swine report expected developments livestock poultry livestock cattle consolidated companion animals horse financial statements companion animals small animals overview major consolidated companies consolidated balance sheet consolidated profit loss statement cash flow statement statement changes group equity notes consolidated financial tatements auditors report h e h r e h l e r p e r p e c v e christian boehringer chairman shareholders committee shareholders perspective independent entrepreneurs boehringer ingelheims shareholders together aim contribute improved health people animals global workforce around people shares ambition maxims keeping company family ownership maintaining independence well readiness focus core businesses secure competitiveness organic growth anchor across generations past years characterised agility momentum willingness change time boehringer ingelheims year history phases markets shaped major changes times especially shareholders readiness bear entrepreneurial risks successfully enabled employees explore new avenues strength company lies capacity innovation key competitive ness innovation sometimes results major steps often many small steps along value chain shareholders able create longterm reliable framework innovation change borne employees clear targets space implementation create foundation employees prepared take responsibility adopting new paths making personal contributions successful year boehringer ingelheim company recorded profitable growth success past year success employees result tireless commitment boehringer ingelheim behalf shareholders would like take opportunity express heartfelt thanks signed christian boehringer chairman shareholders committee k e p e c andreas neumann simone menne joachim hasenmaier hubertus von baumbach allan hillgrove michel pairet left right board managing directors key aspects compare group today boehringer ingelheim years ago observe significant changes part comprehensive transformation focused human pharmaceuticals animal health manufacturing biophar maceutical products correspondingly developed corporate structure aligning business units value innovation drives us forward persistently high investment research development previous years proof boehringer ingelheims clear focus innovation value chains changing require new networks capacity innovation partnerships combine crucial success factor therefore seek collaborate partners even intensely past goal con tinue make significant contribution human animal health future thereby serving customers interests current financial year focus implementing steps outlined acquiring merial yearend reached last milestone realign ment animal health business outcome months successful effort globally highly competitive organisation integration two animal health organisations high priority order consistently expand new market position human pharmaceuticals business continuously working safeguarding market success new established medicines innovative concepts portfolio fill us confidence praxbind brought onto market many countries enables doc tors rare emergency situations reverse effect pradaxa oral anticoag ulant minutes pradaxa thereby product class offers option key aspects field diabetes continuing work highly successfully alliance partner eli lilly company cardiovascular longterm outcome study empareg outcome able demonstrate jardiance treatment type diabetes sig nificantly reduces risk dying cardiovascular diseases even approved us food drug administration european authorities also seen huge potential jardiance updated product information another milestone groundbreaking expansion biopharmaceutical production site vienna austria want expand considerably due com petence developed many decades biopharmaceutical production increasingly significant recognised cornerstone company medium term give priority development human animal health product portfolio technological development lead fundamental changes healthcare sector intend take part shaping long term want achieve significant progress wherever urgent need major therapeutic advances past time able help patients innovative medicines prevention acute treatment strokes parkinsons disease severe pulmonary diseases lung cancer least diabetes drawing successes confident future ability also take away fear associated diseases alzheimers schizophrenia past year changes outlined posed significant challenges organ isation entailed major personal changes many people unaffected enormous additional efforts able close financial year successfully would like take opportunity thank employees commitment creativity passion boehringer ingelheim signed signed signed hhhuuubbbeeerrrtttuuusss vvvooonnn bbbaaauuummmbbbaaaccchhh jjjoooaaaccchhhiiimmm hhhaaassseeennnmmmaaaiiieeerrr aaallllllaaannn hhhiiillllllgggrrrooovvveee signed signed signed sssiiimmmooonnneee mmmeeennnnnneee aaannndddrrreeeaaasss nnneeeuuummmaaannnnnn mmmiiiccchhheeelll pppaaaiiirrreeettt corporate bodies c r p r e b e shareholders committee board managing directors christian boehringer hubertus von baumbach chairman shareholders committee chairman board corporate board division finance christoph boehringer prof dr dr andreas barner erich von baumbach jr chairman board isabel boehringer dr wolfgang baiker corporate board divisions biopharmaceuticals dr mathias boehringer operations prof dr dr andreas barner dr joachim hasenmaier corporate board division animal health corporate board division consumer health care advisory board allan hillgrove egbert appel corporate board division chairman advisory board pharma marketing sales trustee martin hilti family trust corporate board division human pharma president hilti foundation kurt beck simone menne former ministerpresident corporate board division finance dr nikolaus von bomhard dr andreas neumann chairman board management corporate board division human resources mnchener rckversicherungsgesellschaft dr michel pairet dr andreas kreimeyer corporate board division research former member board executive directors nonclinical development research executive director basf se corporate board division innovation jan rinnert chairman board management heraeus holding gmbh group management report boehringer ingelheim group management report consolidated financial statements product portfolio g r u p n g e e n r e p r information group report economic position risk report report expected developments group management report information boehringer ingelheim group companies information group companies group management report information group groups business model boehringer ingelheim familyowned company treat type diabetes also made significant contributions established based ingelheim ger boehringer ingelheims success ofev many focus company research newly introduced offers people development production sale innovative pharma rare fatal respiratory disease idiopathic pulmonary ceuticals improving health quality life contrib fibrosis ipf new treatment option also achieved uting great therapeutic benefit human medicine strong growth animal health affiliated companies employees worldwide group achieved net business aim boehringer ingelheim continue sales eur billion making one drive forward innovative development worlds top pharmaceutical companies existing product portfolio organic growth financial year boehringer ingelheims business activities covered prescription medicines consumer health care animal health biopharmaceuticals industrial custom net sales business eur million ers start exchange boehringer ingel heims consumer health care business chc sanofis prescription medicines animal health business merial took place scheduled thus included figures financial year step marks successful conclusion strategic transaction started exclusive consumer health care negotiations december prescription medicines form core boehringer ingel heims activities medicines boehringer ingelheim animal health long standard treatments cardiovascular diseases respiratory disorders oncology diseases central nervous system immunology companys biggest revenue contributor biopharmaceuticals spiriva used treat chronic obstructive pulmo nary disease copd asthma moreover pradaxa used prevent strokes patients atrial fibrillation well prevention treatment industrial customers sales thromboembolic disorders trajenta jardiance remain impressive trajectory used consolidated financial statements product portfolio net sales region eur million boehringer ingelheim achieved majority sales americas europe regions however revenue region asia australia africa aaa also gaining significance making groups total net sales three biggest markets usa japan germany accounted around sales last year europe research development rd asia line mission statement boehringer ingelheims australia africa primary goal research develop innovative medi americas aaa cines therapies treatment diseases yet satisfactory treatments available aim times make major contribution areas need treatment high occupy lead cooperation external partners ing position major indication areas boehringer ingelheim operates global research network major facilities biberach hanover ingelheim achieve aim boehringer ingelheim besides germany ridgefield st joseph usa vienna rd activities draw global network comprising austria supported two smaller facilities kobe japan academic groups public research institutions biotech milan italy companies addition expanding product portfolio partnership agreements systematic within consumer health care dulcolax buscopan inlicensing technologies products year pharmaton mucosolvan among compa review example boehringer ingelheim agreed long nys best selling medicines past financial year term partnership development nextgeneration oncolytic virus platform austrian company animal health another major pillar boehringer ingel viratherapeutics purchase option agreement en heims business swine vaccine ingelvac circoflex titling boehringer ingelheim acquire viratherapeutics used treat porcine circovirus type signifi upon completion phase clinical development cant product animal health terms sales boost competitiveness area long term boehringer ingelheims rd activities basis boehringer ingelheim acquired animal health business companys success together innovative prowess merial french company sanofi january primary driver behind groups positive growth recent years inhouse research develop biopharmaceuticals business another important ment supplemented external cooperation partner growth area boehringer ingelheim boehringer ingel ships also continue top priority future heims biopharmaceutical activities comprise manu facture ownbrand marketable products financial year employed average actilyse metalyse praxbind process devel people rd sites total opment new biological entities nbes biosimilars eur billion invested research devel one worlds leading companies process opment new medicines corresponding development contract manufacturing commercial groups net sales thus forecast production thirdparty industrial customers level previous year group management report information boehringer ingelheim group companies research development expenditure eur million net sales prescription medicines expenditure eur million prescription medicines net sales average number employees investments tangible assets without investments infrastructure eur million human pharmaceuticals key treatment goal therapeutic area boehringer ingelheim carried research develop reduce risk exacerbations two posthoc analyses ment prescription medicines businesses wisdom study published suggested facilities usa germany austria italy japan gradual reduction dosage inhaled corticosteroids ics result increased risk exacerbation key focus research work patients continued receive spiriva tiotro following indication areas pium laba salmeterol appeared harm small group patients severe severe immunology respiratory disorders copd increased eosinophil blood count frequent cardiometabolic diseases cardiovascular exacerbations metabolic diseases oncology immunooncology new largescale dynagito study also examining diseases central nervous system effect spiolto respimat comparison spiriva respimat case copd exacerbations expenditure rd prescription medicines accounted first results expected net sales generated business tovito trial programme wisdom study boehringer ingelheim continued pursue inten part current study evidence served sive research chronic respiratory disorders basis updated position paper gold com asthma copd ipf able offer affected mittee global initiative chronic obstructive lung patients best possible treatment disease treatment copd gold update recommends therapy longacting anticholin key goal copd therapy enable patients remain ergic lama longacting betaagonist laba physically active longer september find combination included spiolto respimat ings phase iii study physacto presented broad range copd patients gold stages b congress european respiratory society ers show combination spiolto respimat clinical unitinaasthma trial programme physical training change behaviour significantly examined spiriva tiotropium respimat asthma improved functional capacity copd patients completed new data supplement physacto study forms part tovito trial existing evidence confirm spiriva respimat programme examines efficacy safety welltolerated effective many asthma patients spiolto respimat treating copd continuing symptoms despite basic therapy consolidated financial statements product portfolio inhaled corticosteroids ics andor longacting beta approved use children years age agonists laba older included global strategy asthma management prevention global initiative phase ii largescale unitinaasthma trial pro asthma gina gramme included clinical studies worldwide study centres patients including since market approval patients children young people aged worldwide suffering ipf treated ofev nintedanib new posthoc analyses presented annual meeting american academy allergy asthma new analyses pivotal phase iii inpulsis immunology aaaai demonstrated spiriva studies inpulsison followup study well respimat effective addon therapy addition data everyday practice provided evidence basic therapies irrespective individual efficacy ofev broad range patients subtype allergic asthma analyses showed ofev consistently slowed course disease considerable reduction rate data supported publication new fvc decline also significantly reducing risk analysis primotinaasthma studies showed acute ipf exacerbations inpulsison followup spiriva respimat effective independently study also confirmed sideeffects profile inpulsis broad range baseline characteristics used addon case maximum exposure time therapy patients continue display symptoms four years new safety concerns identified despite icslaba moreover june first ipf patients pooled data analysis seven studies phase ii enrolled new study international phase iv study phase iii found safety tolerability profile inmark investigating effect ofev spiriva respimat addon therapy least change certain biomarkers blood examines ics comparable placebo whether biomarkers predict individual clinical course ipf annual meetings american thoracic society ats european respiratory society ers data senscis safety efficacy nintedanib paediatric studies unitinaasthma pro systemic sclerosis largestever study sufferers gramme showed spiriva respimat also effective systemic sclerosis ssc developed interstitial addition basic therapy children young peo lung disease ild connection boehringer ple symptomatic asthma ages ingelheim continuing pursue commitment children symptomatic asthma already examine potential ofev offers forms welltolerated age one progressive fibrotic interstitial lung diseases sep tember european commission ec new data form part applications eu us food drug administration fda granted usa goal extending indications nintedanib orphan drug status treatment sscild spiriva respimat case asthma july boehringer ingelheim pooled cardiovas eu spiriva respimat approved treat cular metabolic diseases therapeutic areas create ment adults continue display asthma symptoms new combined therapeutic area cardiometabolic despite icslaba therapy usa spiriva respimat diseases group management report information boehringer ingelheim group companies key milestone past year inclusion anticoagulant effect pradaxa updated data empareg outcome study data product char reverse ad study subanalyses pre acteristics information jardiance empagliflozin sented various congresses praxbind approved countries around world including usa countries worldwide canada january european commission decided include data european product indication area oncology boehringer ingelheim characteristics information subanalyses successfully advanced research development empareg outcome study presented major pipeline compounds marketed treatments international congresses course year aim providing new treatment options may offer analysis examined effect jardiance new patients added therapeutic value contribute quality deteriorating kidney disease presented ameri life improvements diabetes association ada th scientific sessions published new england journal medicine made huge progress highly competitive time order pursue research lung cancer market also continuing activities potential jardiance field cardiovascular area research development cancers disease boehringer ingelheim eli lilly announced need treatment high afatinib giotrif would initiate two new clinical studies gilotrif secondgeneration medicine treat two sister studies intended examine empagli ment specific type nonsmall cell lung cancer flozin treatment chronic cardiac insufficiency nsclc available patients since patients without diabetes studies product became market leader many markets underway companys diabetes portfolio pro results two major studies luxlung trial gressing schedule include two cardiovascular programme commitment boehringer ingel outcome trials trajenta linagliptin carmelina heims teams worldwide played key role carolina jardiance trajenta luxlung study afatinib compared erlotinib jointly marketed boehringer ingelheim eli lilly tarceva patients squamous cell carcinoma lung improved overall survival rate afatinib field anticoagulation data clinical therapy demonstrated safety profile compara practice published pradaxa dabigatran ble previous studies data resulted etexilat includes independent analysis data approval afanitib new indication moreover clinical practice provided authors work data advanced luxlung study us food drug administration initial find presented confirmed improved profile ings phase ii gloriaaftm register study patients comparison gefitinib iressa presented various congresses course year two randomised clinical studies pradaxa second half boehringer ingelheim decided redual pci recircuit completed return rights joint development marketing recruitment patients results pre olmutinib thirdgeneration active substance sented medical congresses provide treatment nsclc hanmi pharmaceuticals deci insights efficacy safety profile sion made following reassessment clinical pradaxa studies examined patients undergoing data olmutinib considering current pro percutaneous coronary intervention pci stent gress area lung cancer positive egfr implantation redual pci patients atrial mutation fibrillation ablation recircuit praxbind idarucizumab specific drug reversal consolidated financial statements product portfolio boehringer ingelheims second product market order drive forward two substances portfo treatment advanced nsclc nintedanib vargatef lio made progress boehringer ingelheim approved markets worldwide signed global cooperation agreement abbvie examine effect nintedanib types cancer march substances risankizumab bi pivotal lumemeso phase iii study malignant examined various immunological diseases pleural mesothelioma rare type cancer triggered eg psoriasis crohns disease development contact asbestos period many years marketing partnership offers best means ensuring began two medicines reach largest possible number right patients thereby achieve full potential addition products already approved significant progress made oncological development pipe several active substances early clinical line company established series development stage already showing signs offer important partnerships strategic agreements ing strong therapeutic potential patients various sides atlantic goal strengthen immunological diseases inflammatory bowel ing oncology portfolio already delivered impor disease lupus nephritis tant results clinical development animal health therapeutic area central nervous system research development work field ani boehringer ingelheim focuses research identifying mal health boehringer ingelheim concentrates inno functions brain responsible key vative vaccines protection livestock pets symptoms main psychiatric illnesses include well pharmaceutical products focusing schizophrenia alzheimers disease depression treatment pets chronic diseases continue operate complex research field facilities usa germany china mexico number companies recently suffered japan denmark india focus research new setbacks however confident symptom drugs development future therapeutic solu based approach help develop effective therapies tions since many vaccines based local pathogens may useful whole range diseases therefore pathogen variants imperative present focussing initially achieving better key market regions local rd production standing biology brain well rele facilities vant circuitry past year invested expansion research portfolio includes substances influence existing facilities well construction centre disruption glutamatergic signalling pathway clinical research china ames iowa usa occurs case cognitive impairments established site animal health research company connection examining substances moved new research building offers space phosphodiesterase inhibitors influence transmis around employees immediate vicinity sion signals brain camp andor cgmp iowa state university investments demonstrate companys commitment intention sustainably boehringer ingelheim active area immu strengthen position animal health nology research development many years set invest important therapeutic area large number extensive pivotal clinical studies expand capacities launched cases already group management report information boehringer ingelheim group companies successfully completed serves cornerstone production regulatory submissions addition human pharmaceuticals internal research development external projects overarching aims production human phar products also assessed cases integrated maceuticals reliable market launch prod portfolio activities preservation existing ucts routine care patients using highqual products expansion geographical dis ity pharmaceuticals competitive prices therefore tribution another important aspect rd work boehringer ingelheim optimised supply strategy early company began implement strat globally boehringer ingelheims animal health business egy throughout value chain facilities received new product authorisations motto volume value supply net biopharmaceuticals work set rigorously focused made flexi boehringer ingelheim committed strategic deci ble next years reflect requirements sion actively entering biosimilars business businesses production facilities manufac thereby increasing access highquality biolog ture products particular relevance group ics patients around world biosimilars increase whose manufacturing technology requires unique exper range treatment options doctors tise operated production facilities nine coun patients health sector providing vital con tries year review divided tribution efficiency health care systems eleven pharmaceutical three chemical four biophar world patients ' benefit currently con maceutical facilities well one production facility centrating particular first biosimilar monoclonal medical products antibodies immunology oncology two bio similar candidates late clinical development production capacities supplemented stage bi biosimilar candidate humira external contract manufacturers primarily focus adalimumab bi biosimilar candidate manufacture products advanced avastin bevacizumab stage life cycle ensures reliable com petitive supply prescription medicines consumer november published first results health care products close cooperation external pivotal phase iii study bi study bi partners secures boehringer ingelheim access technol demonstrated similar level efficacy safety ogies currently available internal pro comparison humira adalimumab patients duction portfolio enables us focus investments rheumatoid arthritis bi accepted products particularly relevant us review relevant regulatory authorities usa europe fda ema also boehringer ingelheim therefore primarily invested published data phase study biosimilar additional production capacity respiratory dis candidate bi demonstrate bioequivalence ease products spiriva handihaler respimat bi reference product avastin platform cover increasing demand bevacizumab ongoing pivotal phase iii study antidiabetic portfolio boehringer ingelheim invested examining safety efficacy bi com eur million production facilities parison avastin patients advanced nonsmall mexico city koropi greece cell lung cancer consolidated financial statements product portfolio animal health development services chinese international cus field animal health boehringer ingelheim tomers go operation planned first primarily active production network comprising quarter four facilities manufacturing vaccines one facility nutraceuticals supplemented contract man occupational safety environmental ufacturers primarily north central america protection well europe construction new chinese protection employees facilities facility taizhou continuing apace asian environment well sustainable use natural location soon join production network major resources promotion environmental awareness component animal health growth strategy major components companys mission statement facility focus manufacture vaccines prime importance boehringer ingelheim porcine diseases chinese market compliance social environmental aspects anchored corporate philosophy many years biopharmaceuticals company strives maintain natural resources biopharmaceutical activities boehringer ingelheim advocates environmental awareness within germany biberach austria vienna usa fremont outside company observing social ecological china shanghai comprise manufacture concerns way ensure achieve brand marketable products actilyse etalyse sustainable economic success future generations praxbind process development nbes biosimilars one worlds leading compa groupwide company developed binding stand nies process development contract manufacturing ards terms environmental protection health commercial production thirdparty industrial cus safety work internal guidelines reflect respec tomers thereby boehringer ingelheim covers entire tive countryspecific requirements many cases go biopharmaceutical value chain genetic development far beyond standards prescribed law cell followed manufacturing active sub stance finished pharmaceutical product within boehringer ingelheim corporate department product launch global market supply environment health safety sustainability ehss responsible conceptual focus boehringer use capacity production facilities ingelheim characterised negotiations high level boehringer ingelheim met increasing sanofi exchange boehringer ingelheims demand actilyse active substance praxbind consumer health care business sanofis animal health launched markets past financial division merial start corporate ehss year following successful market introduction monitored negotiations order ensure compliance usa europe companys ehss duty care addition comprehensive environmental due diligence process moreover industrialscale cell culture facility implemented facilities regular ehss audits biberach approved manufacture boehringer ingelheims internal facilities customer market product expansion project new premises suppliers contract manufacturers industrialscale biopharmaceutical production facility likewise ensure compliance well site vienna reached milestones international standards pharmaceutical supply chain initi award first official permits enabling ative psci programme supplemented ground breaking ceremony commercial facil code conduct relevant suppliers status ity shanghai china various biopharmaceutical environmental protection occupational safety con group management report information boehringer ingelheim group companies tinuously reviewed potential improvement average number employees region identified basis americas europe part sustainability efforts took part asiaaustraliaafrica aaa independent assessment performance ecovadis awarded silver medal fur ther example continuous improvements field environmental protection extensive work major success factor positive growth group analyse decontaminate soil ingelheim site innovative motivated staff accordingly germany committed actively developing supporting employees order best prepared chal contribution towards reducing global co emis lenges ahead part comprehensive training sions set goal reducing system set great store acquisition entire co emissions compared technical expertise also promoting social skills values part groupwide green initi ative achieved reduction per integration various experiences cultural floor space date energy savings reductions backgrounds personalities boehringer ingelheim emissions creates openness different approaches opinions living vision value innovation health safety employees high priority global company important boehringer ingelheim boehringer ingelheim reflected interna diversity markets reflected workforce tional safety standards safety culture creating working environment embraces diversity practise groupwide safe initiative aims differences one pillars corporate cul reduce number workplace accidents ture boehringer ingelheim contributing factor rolled second wave since focus companys success safety global sales organisation global accident frequency rate afr amounted acci addition competitive salaries boehringer ingelheim dents per million hours worked represents offers stateoftheart benefits employees reduction points benefits include company pension plans flexible homebased work options numerous health employee reporting related benefits significant component corpo boehringer ingelheim employed people rate strategy part talent management ensure worldwide represents decrease employability staff promote wide range previous year regional perspective number opportunities innovation work motivate staff america reduced mainly due sale employees develop individuals us generics business number employ ees europe increased remained stable vocational training always major importance aaa region boehringer ingelheim part understanding social responsibility company offers career opportuni ties great number young people time secure talented wellqualified workforce young professionals backdrop demographic change young professionals started careers consolidated financial statements product portfolio boehringer ingelheim germany different social commitment within company also encouraged scientific technical commercial fields boehringer ingelheim employees coun young people currently enrolled training tries work mmh initiative mmh youth venture programme germany project entrepreneurial skills developed working together designing social entrepreneurship projects one companys aims strengthen appeal actively supported mentors workforce initi boehringer ingelheim top employer current ative supported executive residence eir future employees boehringer ingelheim recip mmh insight india staff development programmes part ient various awards efforts area network partnerships nonprofit organisations received top marks auditors interna social entrepreneurs healthcare sector tional independent top employers institute major hr programme gives young managers opportunity sup categories talent strategy executive develop port participants project facilities specific ment staff planning performance management period time jointly develop implement projects onboarding evidence strong appeal goal develop promote socially aware development opportunities company innovative approach business integrate new per employees potential recruits spectives approaches everyday business social responsibility manufacturer tradition high expertise taking social responsibility beyond business activities field stroke therapy prevention boehringer also important aspect corporate culture ingelheim promoting broader public awareness commitment wellbeing patients employees improved care together patient organisations families focus range projects politics boehringer ingelheim providing infor addition support people need various mation causes consequences strokes initiatives particularly countries regions options prevention act case active company companys activities emergency years last year boehringer also focus protecting maintaining environ ingelheim involved herzenssache ment german chemical industry association schlaganfall taking stroke heart awarenessraising presented boehringer ingelheim responsible initiative organised various projects aware care award companys power station nessraising events initiative launched ingelheim facility associated longterm improve boehringer ingelheim promotes projects ment carbon footprint raise awareness atrial fibrillation associated risk stroke well improving public perception major pillar social commitment mmh initi herzenssache lebenszeit taking life heart ative six years boehringer ingelheim awarenessraising campaign throughout germany partnership ashoka global nonprofit organisation boehringer ingelheim together various foundations aim partnership integrate health associations stroke diabetes fields pro major factor peoples lives around world including viding information risks associated two families social environment aims widespread diseases possibilities preven identify support promising ideas improving tion events towns cities health order achieve making health goal reduce number new cases currently promotes selected social entrepre neurs around world attempting come improve european system handling strokes effective solutions healthcare sector boehringer ingelheim set angels initiative group management report information boehringer ingelheim group companies report economic position together european stroke organisation eso positive economic development continued goal developing european network clinics germany economic output rising upturn equipped handle strokes supported particular significantly greater private public consumer spending well housing invest boehringer ingelheim always actively supported ments moreover increase consumer spending also research science culture continuously affirms improved situation labour market meaning strategy partnerships academic institu number people employment increased tions addition supporting scientific activities scien growth rate rise exports fell short tists also awarded annual boehringer ingelheim previous years level thereby reflects still quite sub fens research award neuroscience heinrich dued economic recovery processes countrys key wieland prize research biologically active sub trading partners stances systems view assume positive eco nomic growth germany continue forecast report economic growth around slowdown growth com parison previous year mainly attributable position decrease number working days weak growth global trade prevent eco macroeconomic environment nomic expansion germany global economy grew pre vious year thereby fell slightly short previous average rate inflation prices years increase well expected trend germany decreased compared previous year measured consumer price index rate infla major industrialised countries economic recovery tion whole eurozone thus higher continued unexpected brexit vote previous year temporarily increase uncertainty financial markets effects real economy limited date addition euro major currencies eurozone japan especially economic output rose boehringer ingelheim group us dollar usd faster production potential expansionary mon japanese yen jpy end year euro etary policy european central bank bank devalued sharply us dollar pre japan well decision implement negative vious year fluctuated usdeur december interestrate policy expand bond buying pro usdeur may overall grammes acted stimulus economic situation emerging economies also largely stabilised euro fluctuated relatively strongly japa china india particular strengthened economic nese yen past financial year reaching output due stabilisation commodity prices annual high january jpyeur euro devalued end recession sight russia latin america significantly yen course year low jpyeur july followed upward reval global economy expected maintain uation fourth quarter moderate growth rate united states well japan eurozone expected maintain sta global pharmaceuticals market registered growth ble levels growth emerging economies around financial year trend ongoing process stabilisation expected continue driven rising demand industrialised countries consolidated financial statements product portfolio cancer medicines products treatment auto sales eur million americas region immune diseases antidiabetic medicines due represents around total sales remains ageing population industrialised countries biggest market boehringer ingelheim decline increasing level prosperity emerging economies sales compared previous year mainly industrys growth remained stable albeit slightly due sale us generics business strong growth weaker previous years recorded asia australia africa aaa region boehringer ingelheim achieved course business revenues eur million region correspond longterm sustainably successful development forms ing stable share around groups total basis securing companys independence revenues europe region showed high sales growth long term combined stable earnings sound eur million also reflects pay financing core boehringer ingelheims ment received development marketing rights within strategic focus previous years based approach scope companys cooperation abbvie principles field immune diseases group made sales europe year characterised significant changes net sales region currency boehringer ingelheim changes also repre eur million change adjusted sented important steps companys future americas completion exchange consumer health care europe business chc sanofis animal health business merial asiaaustraliaafrica turn year biggest change within aaa business portfolio past years transaction significantly improve future market position general sales growth conformed expectations sup field animal health establish us future one ported good results clinical trials largest global players segment able place promising new products market successfully push ahead wellestablished products addition ownership us generics business hand experiencing increasingly transferred hikma pharmaceuticals plc first difficult market situation constantly challenging mar quarter corresponding sales agreement ket access growing price pressure key markets signed july usa japan europe overall company asserted well despite difficult conditions together company abbvie boehringer ingel laid foundations future growth heim agreed longterm global collaboration development two compounds therapeutic area boehringer ingelheim recorded operating income immunology eur million corresponding return sales percentage points pre vious boehringer ingelheim recorded net sales eur years return sales operating income includes million financial year corresponds significant positive negative extraordinary effects increase compared previous years compared previous year increased figure eur million exchange rate develop absolute terms eur million ments foreign exchange markets associated exchange rate effects slight impact currency adjusted boehringer ingelheims growth rate stood group management report report economic position boehringer ingelheim usa particular sales spiriva fell significantly key figures eur million change due price pressure net sales operating income second biggest sales contributor boehringer return net sales ingelheim anticoagulant pradaxa recorded sales results operations eur million corresponds increase past financial year boehringer ingelheims business level activities divided prescription medicines con sumer health care animal health biopharmaceuticals eur million medicine trajenta industrial customers used treatment type diabetes achieved sales excess one billion euros first time net sales businesses currency eur million change adjusted prescription medicines ofev offers people rare fatal respiratory consumer health care disease idiopathic pulmonary fibrosis ipf new treat animal health ment option achieved product authorisation biopharmaceuticals generated sales eur million industrial customers sales net sales eur million change prescription medicines spiriva around total revenue prescription medicines pradaxa main pillar boehringer ingelheims business trajenta jentadueto activities revenues prescription medicines micardis amounted eur million equivalent change around currency adjusted com regard regional distribution sales amer pared previous year well successful icas share around far placement innovative products good market largest market region boehringer ingelheim position established medicines positive sales growth generated net sales eur million corre due receipt payment agreed within scope sponds change compared previous companys cooperation abbvie field year currency adjusted impacted immune diseases continuing experience sale us generics business increasing price pressure however particularly estab lished medicines number major markets overall secondbiggest market europe accounted boehringer ingelheim able assert well revenues eur million sales thus increased difficult environment laid compared eur million foundations growth subject significant exchange rate effects net sales region previous years spiriva used treat chronic eur million change obstructive pulmonary disease copd americas biggest contributor sales achieved reve europe nues eur million within reporting period asiaaustraliaafrica aaa thus fell short level previous year eur million companys biggest sales market consolidated financial statements product portfolio asia australia africa aaa region achieved sales adjusted compared previous year achieving eur million equivalent total sales eur million total sales prescription medicines region showed increase compared last year animal health currency adjusted revenues products animal health business increased eur million corresponding consumer health care increase previous year currency consumer health care sales increased com adjusted sales products livestock accounted pared previous year currency adjusted largest share eur million corresponding business boehringer ingelheim generated reve around entire animal health segment nues amounting eur million pet segment revenues amounted eur million net sales eur million change biggest sales contributors consumer ingelvac circoflex health care segment dulcolax buscopan ingelvac prrs pharmaton mucosolvan products generated metacam revenue significantly eur million duramune previous year dulcolax biggest seller sales eur million buscopan also showed increase past financial year growth animal health segment sig generated sales eur million positive results nificant americas region accounting also achieved pharmaton sales increasing total sales biggest sales market boehringer eur million ingelheim business grew currency adjusted eur million us market net sales eur million change important country boehringer ingelheim sales dulcolax increased eur million buscopan pharmaton boehringer ingelheim also saw revenues grow europe mucosolvan increasing eur million rise currency adjusted accounting regions europe generated highest sales total revenues animal health business sales increased eur million corresponds share every country particularly germany global sales consumer health care business sales last year increase currency adjusted aaa region also reported positive growth compared aaa region ended financial year sales previous year recording sales eur mil amounting eur million increase lion corresponds around boehringer compared previous year currency adjusted ingelheim 's total animal health sales china particular market therefore accounted able achieve growth net sales boehringer ingelheims consumer health care business amounting eur million americas region third largest sales market consumer health care business ended financial year raise revenues currency group management report report economic position boehringer ingelheim biopharmaceuticals changes interest rates related conversion sales biopharmaceutical contract manufactur average interest rate discounting pension plan ing amounted eur million represents growth obligations compared previous year income taxes developed line operating industrial customers sales financial result increasing eur million tax industrial customer business consists third expenses amounted eur million increase party businesses field pharmaceutical chem comparison eur million particularly results ical production sales pharma chemicals sales higher results us companies provision eur million achieved corresponding tax risks must noted regard increase revenue compared provisions german commercial law shareholders per previous year sonal taxes arising group business activities may recognised tax expenses instead taxes presentation expenditure income presented part withdrawals group equity operating expenses boehringer ingelheim increased taking extraordinary effect account actual eur million financial year repre tax ratio markedly higher figure shown senting rise compared previous year profit loss statement cost materials higher previous year eur million coming eur million financial year group profit boehringer corresponding cost materials ratio makes ingelheim totalled eur million corresponding personnel expenses amounted eur million increase previous years level corresponding personnel cost ratio eur million percentage points lower pre vious year financial position boehringer ingelheims financial management instruments depreciation amortization recorded increase methods aimed securing liquidity minimising eur million eur million oper financial economic risks optimising cost ating expenses rose compared previous capital appropriate capital structure finan year coming eur million among items cial activities therefore geared towards supporting cost category includes commission licence pay business strategy ments dependent sales global company exchange rate volatility signifi operating income amounted eur million cant impact boehringer ingelheims financial perfor previous year eur mil mance importance us business asso lion influenced significant positive nega ciated supply relationships mean exchange rate tive extraordinary onetime effects sale us generic development us dollar constitutes greatest indi business license payments abbvie expenses legal risks vidual risk within framework groupwide financial adjusted effects previous years reporting foreign exchange risk calculated hedged level thus operating income met expectations derivative financial instruments nature scope measures set group guidelines reporting period financial result amounted regularly discussed approved relevant eur million eur million committee standardised process previous year largely due effect consolidated financial statements product portfolio investments great importance boehringer ingel cash flow led increase liquidity eur mil heim strategic point view continuous investment lion eur million requirement longterm success develop ment company forms basis profita net assets ble growth business divisions financial year boehringer ingelheims total assets amounted eur million increase total eur million invested tangible eur million compared pre intangible assets year review vious year tangible intangible assets totalled eur million financial year boehringer ingelheim invested eur million expansion production end year financial investments amounted capacity respimat soft mist inhaler dort eur million corresponds increase mund ingelheim facilities germany boehringer eur million previous years value invento ingelheim microparts gmbh dortmund manufactures ries showed growth eur million trade respimat soft mist inhalation system receivables declined eur million eur filled relevant active substances million liquid funds including securities within pharmaceutical production facility ingelheim ready current assets stood eur million previous year global sales eur million boehringer ingelheim invested signifi due aforementioned changes cash cash cant growth market china group continued equivalents group equity amounted eur mil investment programme expansion biopharma lion therefore fully covers tangible ceutical animal health manufacturing facilities intangible assets addition equity pension pro shanghai taizhou visions longterm liabilities also available group long term total three items investments made research facilities germany amounted eur million representing austria usa reflect top priority share total assets consequently longterm research development fields human disposable capital covers intangible tangible assets animal medicines boehringer ingelheim inventories trade receivables cash flow amounted eur million provisions higher last year represents decline cash flow eur million liabilities reduced operating activities increased eur million eur eur million previous year million mainly due receipt payment agreed within scope companys coop status already shown financial position remains eration abbvie field immune diseases resoundingly positive balance sheet previous years meant investments could respective balance sheet ratios sum boehringer financed entirely funds generated company ingelheims net assets financial earnings position total eur million invested tangible confirm credentials soundly financed profita assets eur million intangible assets terms ble company cash flow financing activities recorded flow funds amounting eur million mainly due loan repayments overall changes group management report risk report boehringer ingelheim risk report individual risks important risks boehringer ingelheim risk opportunity management exposed broken following specific cat aim risk management system implemented egories financial risks legal risks production environ boehringer ingelheim identify businessspecific risks mental risks personnel risks sectorspecific risks particular risks jeopardise continued exist ence company early possible assess risks identified concrete reduce reasonable level means suit appear controllable means specific manage able measures ment procedures term abstract used case risks completely controlled even assessing risks context holistic risk means targeted management procedures regardless management also endeavour take account probability occurrence resulting opportunities opportunity management based strategies objectives company individ financial risks ual businesses operating business units inte relevant financial risks broken gral part groupwide planning management follows currency risks credit countryspecific risks systems responsible businesses func well management financial investment risks tions bear direct responsibility early systematic identification analysis use opportunities currency risks boehringer ingelheim researchdriven innova global orientation business activities results tive pharmaceutical company current research currency risks due exchange rate volatility particularly development activities naturally considered relevant regard us dollar japanese yen group opportunity relevant projects already illus monitors quantifies risks regular intervals trated research development chapter making predictable future business means relevant hedging strategies appropriate financial persons responsible key businesses func instruments forward exchange contracts tions included process calculating assess resultant risks subsequently designated con ing risks groupwide risk information system crete therefore controllable ensures identified risks analysed assessed carefully following appropriate classification credit countryspecific risks various categories adequate countermeasures initi boehringer ingelheim exposed various credit ated implementation consistently monitored countryspecific risks result international business activities portfolio trade accounts receivable year review internal auditing performed tar trade accounts payable identified geted routine audits well extraordinary audits around extraordinary risks group beyond usual level world addition adherence legal requirements sector applies possible default risks internal group guidelines main focal points receivables largely hedged economic functionality systems effectiveness internal risks continue carefully track credit coun controls prevention loss assets effi tryspecific risks position respond negative ciency structures processes corresponding adjust changes timely manner risks therefore ments optimisations initiated necessary regarded concrete consolidated financial statements product portfolio management financial investment risks breaches taken necessary precautions allow group pursues defensive investment strategy us detect threats early stage commencing management financial assets reflected appropriate countermeasures defend legal position orientation portfolio focused euro using legal means available us risks pean economic monetary union emu government regarded concrete bonds top credit ratings shortterm investments selected banks results concrete production environmental risks thus controllable risk quality management system compliance pro cesses continuously optimised close cooperation legal risks relevant authorities order ensure compli business activities group exposed legal ance cgmp standards current good manufacturing risks distinction made regulatory liability practices future risks area continue patent protection risks high significance group classified abstract regulatory risks boehringer ingelheim exposed risks arising legal order guarantee supply products disputes proceedings well official investigations market implemented measures guarantee legal administrative decisions ongoing future reliable highquality supplies internal external proceedings predicted regard resultant customers addition supplier management risks abstract procurement side also involves building internal standby capacities result see risk concrete liability risks marketing sale pharmaceuticals exposed risks areas environment health safety sus potential product liability risk boehringer ingelheim tainability ehss preemptively minimised currently product liability insurance companys ensuring global adherence high safety standards risk profile absolutely guarantee however appropriate emergency plans drawn insurance coverage maintained reason possible incidents kind practised sub able cost acceptable conditions sufficient jected comprehensive quality testing regular inter protect boehringer ingelheim claim loss vals result measures risks classed potential claims losses concrete furthermore product liability claims could tie sub personnel risks stantial financial resources management capacity boehringer ingelheim companies exposed detrimental companys image event demographic change resultant risk affected market considers product unsafe ineffec lack appropriately qualified personnel risk tive result unexpected side effects regard substantial impact companys business risk abstract activities potential risk therefore included longterm planning process many years patent protection risks acquired strategic significance result boehringer protection innovations trademark brand ingelheim counters risk means comprehensive patent rights particular importance boehringer personnel concept regardless ethnic background ingelheim research company commercial pro gender religion offer company employees devel tective rights increasingly target attacks opment opportunities based vocational skills social group management report risk report boehringer ingelheim report expected developments report expected expertise personal aptitudes willingness take responsibility accordance needs com developments pany view countermeasures described risk regarded concrete year review intense challenging sectorspecific risks time boehringer ingelheim laid boehringer ingelheim exposed business risks specific foundations sustainable development long pharmaceutical industry risks mate term growth company several major decisions rialised past financial year changes health care system usa increasing significance consistent focus business innovationori result impact boehringer ingelheim ented fields attested strategic exchange sanofis continue classed abstract animal health business merial boehringer ingel heims consumer health care business chc contract addition loss exclusivity products estab exchange signed june trans lished market risks associated devel action successfully closed january opment registration new products risks transaction improve competitiveness ani increasingly include changing restrictive require mal health business industrys important growth ments relating pricing reimbursement many markets establish one largest sales markets frequently prices pharmaceutical global players business able offer products subject state monitoring customers worldwide even innovation regulation also price pressure cheaper added value high level pooling comple generic drugs caused state reimbursement sys mentary product portfolios merial boehringer tems boehringer ingelheim therefore keeping close ingelheim existing technology platforms vaccines eye various changes sales markets antiparasitics well pharmaceutical speciality already responded current developments respec products tive costsaving efficiencyimproving measures besides increasing political unreliableness volatility overall statement risk situation difficult market environment increased unpredict current perspective aware risks ability business posed major challenges alone conjunction risks could lead entire pharmaceutical industry continue require impairment companys assets financial position significant attention boehringer ingelheim earnings could jeopardise continued exist regard competitiveness ence boehringer ingelheim important therefore retain scope growth innovation continue successful market future regard many changes healthcare systems increasing price pressure particularly well established medicines many major markets regard increasing challenges market access new products expect see low growth impetus pharmaceutical industry coming year boehringer ingelheim asserted despite difficult condi consolidated financial statements product portfolio tions laid foundations growth cost base order create potential investments integration merials business assume secure companys longterm success sales animal health division difficult market environment one hand double compared previous year potential resulting measures introduced make countervailing effect well promising new product launches sale companys consumer health care business plan see operating income special sanofi make significant contribution factors last years level based current considerable yearonyear increase revenues business structure results expect expect see overall terms current financial year considerable impact major oneoff effects adjustment currency effects results essentially due sale consumer health care business simultaneously acquisition research development costs remained high sanofi 's animal health business overall anticipate keeping strategy drive growth promote strengthening overall group 's financial capability new products future primarily products integrating merial business research development facilities invest area care close investigation thera familyrun company boehringer ingelheims primary peutic benefit associated prospects success aim maintain firms independence competi comprehensive portfolio prospective products tiveness longterm sustainable organic promising study outcomes along newly approved growth still takes precedence shortterm profit tar products significant sales potential justifies high gets confident achieve ambitious level investment research development targets thanks great innovative strength based plan invest research development new comprehensive portfolio prospective products global pharmaceutical products similar level year presence support highly qualified moti review based current business structure vated employees current product launches expansions emerging markets boost growth areas addition patent expiry attacks patents business stand vision value major challenges facing researchdriven pharmaceutical innovation research develop innovative products industry increasing amount investment rd offer high medical benefits bring well bigger hurdles increased costs associated market aim endeavours make new medi product approvals context increas cines available enable doctors treat patients ing cost pressure healthcare system effectively currently possible singled particular leading decreasing willingness adequately recognise large amounts invested development new medicines result price pressure major markets prescription medicines conjunction longer planning development cycles new products makes business less predictable requires us recognise seize opportunities quickly one hand subjecting strategies structures continual monitoring adjustments end instigated initiatives past years accelerate reaction change reduce organisational complexities well lower consolidated financial statements boehringer ingelheim consolidated financial statements product portfolio c n l e f n n c l e e n overview major consolidated companies consolidated balance sheet consolidated profit loss statement cash flow statement statement changes group equity notes consolidated financial statements auditors report overview major consolidated companies boehringer ingelheim overview major consolidated companies c h boehringer sohn ag co kg boehringer ingelheim boehringer ingelheim boehringer ingelheim gmbh europe gmbh international gmbh germany p r austria p r austria r boehringer ingelheim boehringer ingelheim rcv forschungsinstitut fr molekulare pharma gmbh co kg gmbh co kg vienna pathologie gesellschaft mbh ingelheim vienna boehringer ingelheim boehringer ingelheim pharma gesmbh vienna vetmedica gmbh ingelheim belgium boehringer ingelheim microparts gmbh dortmund czech republic scs boehringer ingelheim comm v brussels boehringer ingelheim boehringer ingelheim sro biopharmaceuticals gmbh prague ingelheim china p boehringer ingelheim veterinary finland boehringer ingelheim research center gmbh co kg international trading shanghai hanover boehringer ingelheim co ltd shanghai finland ky espoo philippines norway boehringer ingelheim boehringer ingelheim phil inc manila norway ks asker poland boehringer ingelheim spzoo warsaw distribution p production r research development sole personally liable managing shareholder boehringer ag product portfolio c h boehringer sohn grundstcksverwaltung gmbh co kg boehringer ingelheim auslandsbeteiligungs gmbh argentina r france p netherlands p taiwan boehringer ingelheim sa boehringer ingelheim boehringer ingelheim bv alkmaar boehringer ingelheim buenos aires france sas paris taiwan ltd taipeh boehringer ingelheim animal health operations bv alkmaar australia greece p thailand boehringer ingelheim pty ltd boehringer ingelheim ellas ae new zealand boehringer ingelheim north ryde athens thai ltd bangkok boehringer ingelheim nz ltd auckland brazil p india turkey boehringer ingelheim brasil boehringer ingelheim portugal boehringer ingelheim ilac quimica e farmaceutica ltda india private ltd mumbai ticaret istanbul paulo boehringer ingelheim lda lisbon solana agro pecuaria ltda unilfarma lda lisbon indonesia p united kingdom arapongas pt boehringer ingelheim boehringer ingelheim ltd singapore indonesia jakarta bracknell canada boehringer ingelheim boehringer ingelheim singapore pte ltd singapore ireland usa p r canada ltd burlington boehringer ingelheim boehringer ingelheim corp south africa ireland limited dublin ridgefield connecticut chile boehringer ingelheim pty ltd boehringer ingelheim boehringer ingelheim ltda randburg pharmaceuticals inc italy p r santiago de chile ingelheim pharmaceuticals pty ridgefield connecticut boehringer ingelheim ltd randburg boehringer ingelheim italia spa reggello usa corporation china p bidachem spa ridgefield connecticut south korea boehringer ingelheim shanghai fornovo giovanni boehringer ingelheim pharmaceuticals co ltd shanghai boehringer ingelheim korea ltd vetmedica inc boehringer ingelheim china seoul st joseph missouri japan p r investment co ltd shanghai boehringer ingelheim boehringer ingelheim vetmedica nippon boehringer ingelheim spain p fremont inc china investment co ltd shanghai co ltd tokyo fremont california boehringer ingelheim animal health ssp co ltd tokyo boehringer ingelheim espaa sa barcelona operations china co ltd taizhou boehringer ingelheim vetmedica japan co ltd boehringer ingelheim sa barcelona colombia p tokyo europharma sa barcelona boehringer ingelheim boehringer ingelheim sa seiyaku co ltd yamagata laboratorios fher sa barcelona bogot boehringer ingelheim japan inc tokyo sweden denmark p boehringer ingelheim ab stockholm boehringer ingelheim mexico p r danmark copenhagen boehringer ingelheim switzerland promeco sa de cv boehringer ingelheim ecuador mexico city schweiz gmbh basel boehringer ingelheim vetmedica boehringer ingelheim del ecuador pharmaton sa lugano sa de cv guadalajara cia ltda quito consolidated financial statements consolidated balance sheet boehringer ingelheim consolidated profit loss statement c h boehringer sohn ag co kg ingelheim consolidated balance sheet assets millions eur notes intangible assets tangible assets financial assets fixed assets inventories accounts receivable assets securities cash cash equivalents current assets deferred charges prepaid expenses deferred taxes total assets liabilities equity millions eur notes shareholders capital group reserves balance sheet currency conversion difference group profit equity attributable parent company noncontrolling interests group equity difference capital consolidation provisions accounts payable loans liabilities deferred charges deferred taxes total liabilities equity explanation see relevant section notes consolidated financial statements product portfolio c h boehringer sohn ag co kg ingelheim consolidated profit loss statement millions eur notes net sales changes finished goods work process work capitalized operating income total revenues cost materials personnel expenses amortisation intangible assets depreciation tangible assets operating expenses operating income financial income holding income income taxes income taxes income taxes net income noncontrolling interest group profit explanation see relevant section notes consolidated financial statements due legal requirements disclosure shareholders personal taxes arising consolidated business activities tax expenses allowed taxes shown withdrawals accrued group capital consolidated financial statements cash flow statement boehringer ingelheim tatement changes group equity c h boehringer sohn ag co kg ingelheim cash flow statement millions eur income taxes including thirdparty share amortisation intangible assets depreciation tangible assets change provisions pensions cash flow change provisions noncash income expenses income due divestiture consolidated companies gain loss disposals fixed assets change inventories change accounts receivable assets related investing financing activities change trade accounts payable liabilities related investing financing activities interest income interest expenses net income investments incomeexpenses extraordinary magnitude significance income taxes cash receipts extraordinary magnitude significance income taxes paid cash flow operating activities investments intangible assets investments tangible assets investments noncurrent financial assets proceeds disposals tangible assets proceeds disposals noncurrent financial assets cash receipts due divestiture consolidated companies interest received income dividends cash flow investing activities product portfolio c h boehringer sohn ag co kg ingelheim cash flow statement millions eur cash receipts grants interest paid cash payment owners parent entity cash repayments loans cash flow financing activities change liquid funds cash relevant transactions changes liquid funds due exchange rate movements financial funds financial funds excl fixedasset securities liquid funds securities within fixed current assets source funds use funds statement changes group equity equity attri thereof butable non thereof shareholders accrued currency parent controlling currency group millions eur capital group capital effects company interest effects equity balance contributions withdrawals net income changes balance contributions withdrawals net income changes balance shareholders capital consists equity c h boehringer sohn ag co kg c h boehringer sohn grundstcksverwaltung gmbh co kg capital consists limited partners capital contribution shareholders personal taxes arising consolidated business activities shown withdrawals accrued group capital items statement changes equity show value due rounding millions eur disclosed shareholders capital includes limited partners december negative capital account one limited partner amount eur million shown net item within consolidated retained earnings liability limited partner reinstated amount eur consolidated financial statements notes boehringer ingelheim c h boehringer sohn ag co kg ingelheim notes consolidated financial statements principles methods general principles consolidated financial statements boehringer ingelheim financial year prepared accordance section german commercial code hgb line legal requirements prepare consolidated financial statements group management report section et seq hgb provisions german act transformation eu directive bilrug applied first time accordance section hgb consolidated financial statements consist consolidated balance sheet consolidated profit loss statement notes consolidated financial statements cash flow statement statement changes equity consolidated financial statements prepared euro accordance section conjunc tion section hgb improve clarity transparency consolidated financial statements individual items con solidated balance sheet consolidated profit loss statement combined items presented explained separately notes additional disclosures required individual items also found notes registry information parent company registered name c h boehringer sohn ag co kg headquarters ingelheim commercial register mainz district court number hra information companies included consolidation parent company boehringer ingelheim group c h boehringer sohn ag co kg ingelheim boehringer ag ingelheim sole personally liable managing shareholder company besides c h boehringer sohn ag co kg c h boehringer sohn grundstcksverwaltung gmbh co kg whose general partner controlled c h boehringer sohn ag co kg boehringer ingelheim group consists total affiliated companies germany abroad addi tion c h boehringer sohn ag co kg c h boehringer sohn grundstcksverwaltung gmbh co kg companies c h boehringer sohn ag co kg directly indirectly holds majority voting rights included consolidated financial statements full consolidation rules product portfolio accordance section hgb companies included consolidation report ing year individually collectively insignificant terms net assets financial position group earnings total amount sales equity net income year companies included consolidation account less aggregated group financial statements totals two companies ongoing restrictions control due terms articles association companies consolidated accordance section hgb associate companies valued equity accordance section hgb due lack significance total number affiliated companies decreased two compared previous year four companies founded two companies sold two companies merged two companies liquidated usamerican companies roxane laboratories inc ohio boehringer ingelheim roxane inc ohio sold effective date th februar day sale net assets two compa nies amounted eur million amount comprises tangible intangible assets amounting eur million inventories amounting eur million receivables assets amounting eur million provisions amounting eur million liabilities amounting eur million effects sale companies commented respective notes profit loss statement significant following subsidiaries exempted reporting disclosure obligations section hgb boehringer ingelheim gmbh ingelheim boehringer ingelheim europe gmbh ingelheim boehringer ingelheim secura versicherungsvermittlungs gmbh ingelheim boehringer ingelheim grundstcksgesellschaft mbh ingelheim boehringer ingelheim finanzierungs gmbh ingelheim boehringer ingelheim rd beteiligungs gmbh ingelheim boehringer ingelheim venture fund gmbh ingelheim boehringer ingelheim invest gmbh ingelheim following subsidiary companies exempt duty prepare disclose annual financial statements management reports accordance section b hgb c h boehringer sohn ag co kg ingelheim c h boehringer sohn grundstcksverwaltung gmbh co kg ingelheim boehringer ingelheim pharma gmbh co kg ingelheim c h boehringer selbstmedikation kg ingelheim boehringer ingelheim veterinary research center gmbh co kg hanover consolidated financial statements notes boehringer ingelheim consolidation methods inventories fixed assets receivables liabilities income expense items transactions companies included consolidation eliminated part debt consolidation procedures accordance section hgb procedures eliminate intercompany profits accordance section hgb income expenses consolidation procedures accordance section hgb revaluation method applied including subsidiary companies consolidation first time accordance section hgb companies included consolidation first time date company became subsidiary carrying amount shares held parent company offset corresponding equity subsidiary equity carried amount fair value assets liabilities prepaid expenses deferred income special reserves included consolidated financial statements time consolidation remaining balance offsetting capitalised goodwill currency translation assets liabilities resulting foreign currency transactions translated using average spot exchange rate balance sheet date realisation principle section conjunction section halfsentence hgb historical cost convention section conjunction section sentence hgb applied items remaining term one year consolidated financial statements financial statements foreign subsidiaries domiciled state outside eurozone denominated foreign currency converted euro accordance section hgb using modified closing date rate method using modified closing date rate method asset liability items annual financial statements prepared foreign currency translated euros using average spot exchange rate balance sheet date exception equity translated using historical rate items included profit loss statement translated euros using average rate resulting translation difference generally reported within consolidated equity reserves balance sheet currency conversion difference annual financial statements countries hyperinflation expected foreign currency effects already recognised within currency translation accordance section hgb financial statement ii level improve true fair view consolidated financial statements exchange rates groups important currencies changed follows reporting year basis eur closing rate average annual rate us dollar japanese yen pound sterling canadian dollar product portfolio accounting policies fixed assets acquired intangible assets tangible fixed assets carried cost less scheduled straightline amortisa tion depreciation determined consideration technical economic circumstances based following useful lives intangible assets years buildings years technical equipment machinery years equipment operating office equipment years straightline depreciation amortisation used consolidated financial statements additional writedowns recorded reflect impairments value assets considered permanently impaired production costs include materials labour manufacturing costs appropriate portion materials labour overheads depreciation fixed assets extent caused production capitalised intangible assets finite useful lives useful life ten years applied goodwill boehringer ingelheim korea ltd acquired past experience products sales markets together business conditions boehringer ingelheim korea ltd indicates presents true fair view financial assets essentially included shareholder rights securities loans carried lower cost fair market value impaired current assets prepaid expenses inventories carried lower cost fair market value raw materials consumables supplies capitalised lower average acquisition prices fair market value balance sheet date finished goods work progress measured production cost basis individual calculations taking account directly attributable costs materials direct labour costs special direct costs appropriate share production materials overhead costs depreciation goods resale valued lower either purchase cost fair market value identifiable risks inventory assets arising aboveaverage storage periods diminished marketability lower replacement costs taken account recording appropriate valuation adjustments inventories valued lossfree ie deductions made expected sales prices reflect costs yet incurred consolidated financial statements notes boehringer ingelheim receivables assets recognised cost less allowances specific risks general credit risk lowinterest noninterestbearing receivables term one year discounted securities classified current assets include securities recognised lower cost quotedmarket prices reporting date cash cash equivalents consisting cash balances banks cheques recognised lower cost fair market value deferred charges prepaid expenses recorded accordance section hgb include expenses paid advance respect defined period time balance sheet date deferred charges recorded accordance section hgb include proceeds represent income respect defined period time balance sheet date difference capital consolidation difference capital consolidation recognised following acquisitions march august value net assets acquired exceeded purchase prices paid value negative difference acquisition companies amounted eur million january increased acquisition company acquired august eur million negative difference acquisition companies amortised estimated period ten years release negative difference acquisition companies eur mil lion financial year eur million shown operating income release consistent depreciation amortisation excess assets date acquisition product portfolio group reserves group reserves include retained earnings consolidated subsidiaries prior years consoli dation entries affect earnings related previous years provisions tax provisions provisions include uncertain liabilities expected losses executory con tracts carried amount required settle obligation based reasonable prudent com mercial judgement ie including future cost price increases provisions remaining maturity one year discounted using matchedterm average market interest rate case pen sion provisions interest rate results last ten years case provisions last seven years accordance rckstellungsabzinsungsverordnung german regulation discounting provisions liabilities liabilities recognised settlement amount deferred taxes calculate deferred taxes arising temporary quasipermanent differences carrying amounts assets liabilities prepaid expenses deferred charges commercial balance sheet carrying amounts tax purposes tax loss carryforwards amounts resulting tax benefits expenses time differences reverse measured using tax rates specific respective consolidated company deferred tax balances discounted differences due consolidation measures accordance sections hgb also measured using company specific tax rates applicable time expected reversal difference deferred tax assets loss carryforwards taken account likely used within next five years deferred tax assets liabilities reported without offsetting consolidated financial statements notes boehringer ingelheim notes consolidated balance sheet intangible assets acquired concessions advance millions eur similar rights goodwill payments total procurementmanufacturing costs balance currency conversion difference changes consolidated companies additions disposals reclassifications balance currency conversion difference changes consolidated companies additions disposals reclassifications balance accumulated depreciation balance currency conversion difference changes consolidated companies additions writeups disposals reclassifications balance currency conversion difference changes consolidated companies additions writeups disposals reclassifications balance book value book value product portfolio tangible assets advance technical facilities payments land facilities operating construction millions eur buildings machines equipment progress total procurementmanufacturing costs balance currency conversion difference changes consolidated companies additions disposals reclassifications balance currency conversion difference changes consolidated companies additions disposals reclassifications balance accumulated depreciation balance currency conversion difference changes consolidated companies additions writeups disposals reclassifications balance currency conversion difference changes consolidated companies additions writeups disposals reclassifications balance book value book value consolidated financial statements notes boehringer ingelheim financial assets investments loans investments affiliated affiliated related advance investment millions eur companies companies companies payments securities loans total procurementmanufacturing costs balance currency conversion difference changes consolidated companies additions disposals reclassifications balance currency conversion difference changes consolidated companies additions disposals reclassifications balance accumulated amortisation balance currency conversion difference changes consolidated companies additions writeups disposals reclassifications balance currency conversion difference changes consolidated companies additions writeups disposals reclassifications balance book value book value previous year loans item include loans shareholders product portfolio inventories millions eur raw materials supplies unfinished goods finished goods goods resale advance payments suppliers accounts receivable assets residual residual term term millions eur year year trade accounts receivable receivables affiliated companies receivables related companies assets assets item includes receivables shareholders eur million previous year eur million receivables affiliated companies almost exclusively consist receivables loans receivables related companies essentially consist trade accounts receivable provisions millions eur pension provisions similar obligations tax provisions provisions consolidated financial statements notes boehringer ingelheim provisions pensions similar obligations provisions pensions similar obligations determined basis actuarial calculations using projected unit credit method taking account future adjustments salaries pensions addition local biometric data eg germany mortality tables g published prof dr klaus heubeck pension obligations significant countries calculated basis following actu arial parameters december germany usa japan discount rate salary increase pension increase discounting rates determined reference average market rates year maturities accordance german regulation discounting provisions march interest rates used discount significant foreign pension obligations usa japan determined comparable param eters line german regulation discounting provisions march difference calculated accordance section hgb amounts eur million equiv ilant amount resulting modified period interest discounts rate seven ten years offset income plan assets well interest expenses resulting increase provision plan assets intended solely cover pension similar obligations unavailable cred itors plan assets defined section sentence hgb measured fair market value essentially derived stock market prices offset underlying pension similar obliga tions fair market value plan assets balance sheet date eur million related amount pension obligations similar obligations eur million gains losses plan assets interest expense relating pension similar obligations offset accordance sec tion sentence hgb total eur million earnings plan assets eur million inter est expense relating pension similar obligations included financial result tax provisions tax provisions also include provisions double taxation risks significantly increased following implementation national tax law actions plans organisation economic cooperation development oecd part international initiative known action plan base erosion profit shifting beps product portfolio accounts payable loans residual term residual term less greater greater less millions eur year year years year bank loans accounts payable trade accounts payable advance payments received accounts payable affiliated companies accounts payable related companies liabilities taxes eur million social security liabilities eur million previous year liabilities secured mortgages similar collateral rights balance sheet date end year liabilities shareholders eur million previous year eur million presented within liabilities accounts payable affiliated companies include loans amounting eur million previous year eur million trade accounts payable amounting eur million previous year eur million consolidated financial statements notes boehringer ingelheim notes consolidated profit loss statement structure consolidated profit loss statement based total cost format taxes included operating expenses reported net sales comparable figures previous year result firsttime application german act transformation eu directive bilrug section hgb following bilrug amendments applied previous year net sales previous year would amounted eur million operating income would decreased amount order provide better insight earnings position expenditure services reclassified operating expenses material expenses improve comparability previous years figure also adjusted amount eur million revenues include eur million oneoff payments received connection cooperation agreement operating income includes exceptional income sale two us subsidiaries eur million addition group result fiscal year impacted expenses increase provisions legal tax risks amount eur million net sales business business segment millions eur prescription medicines consumer health care animal health biopharmaceuticals industrial customers sales geographic region millions eur europe germany americas usa asia australia africa japan net sales reporting period included net sales deconsolidated companies roxane laboratories inc ohio boehringer ingelheim roxane inc ohio amounting eur million previous year eur million product portfolio operating income operating income includes income currency translation eur million previous year eur million cost materials millions eur costs raw material supplies goods resale expenditure services cost materials reporting period included cost materials deconsolidated companies roxane laboratories inc ohio boehringer ingelheim roxane inc ohio amounting eur million previ ous year eur million personnel expenses millions eur wages salaries social benefits retirement benefits retirement benefits interest effects measurement provision pensions similar obligations shown separate item financial income average headcount production administration marketing sales research development apprentices amortisation intangible assets depreciation tangible assets amortisation intangible assets depreciation tangible fixed assets include extraordinary writedowns eur million previous year eur million operating expenses operating expenses include expenses currency translation eur million previous year eur million consolidated financial statements notes boehringer ingelheim addition operating expenses also include increase provisions legal risks restructuring well thirdparty services research development medicine marketing purposes administrative expenses fees contributions commissions rent freight expenses repairs carried third parties operating expenses reporting period included operating expense deconsolidated companies roxane laboratories inc ohio boehringer ingelheim roxane inc ohio amounting eur million previous year eur million financial income millions eur interest expense relating pensions similar obligations provisions interest expense similar expenditure interest expense similar expenditure amortisation loss disposal financial assets shortterm investments income investment securities longterm loans interest income similar proceeds holding income millions eur writeoffs financial assets income related companies disposal related companies income taxes millions eur income taxes deferred taxes current income taxes essentially include corporation trade tax expenses companies included consolidation result conclusion profit transfer agreements significant german corporations included trade corporation tax group parent company c h boehringer sohn ag co kg since january income taxes shareholders c h boehringer sohn ag co kg incurred operating income reported consolidated profit loss statement tax product portfolio expenses represent trade income tax affected companies applies primarily fully consolidated german partnerships total deferred tax assets amounted eur million balance sheet date previous year mil lion deferred tax assets primarily relate differences carrying amounts recognised provisions pensions rebates intercompany elimination claims relating losses carried forward tax credit fixed assets inventories deferred tax liabilities eur million previous year eur million recognised primarily relate differences carrying amounts tangible assets inventories provisions net income net income positively influenced priorperiod operating income essentially reversal provisions eur million previous year eur million negatively influenced priorperiod operating expenses eur million previous year eur million notes cash flow statement cash flow statement shows changes cash cash equivalents cash longterm securities investments classified current assets sold time boehringer ingelheim group resulting cash outflows reporting year accordance german accounting standard cash flow statement drs cash flow statement broken according cash flows operating activities cash flows investing financing activities changes balance sheet items affiliated companies included translated using average rates year balance sheet cash cash equivalents carried closing rate effect exchange rate changes cash cash equivalents shown separately financial funds comprise financial assets remaining maturity excess months date acquisition financial assets converted cash shortterm financial funds comprise following items millions eur cash cash equivalents securities financial assets financial funds include cash equivalents eur million restricted disposal consolidated financial statements notes boehringer ingelheim furthermore payment made escrow account eur million escrow account included financial funds financial year interest eur million previous year eur million received eur million previous year eur million interest paid tax payments amounted eur million previous year eur million course sale us generic business boehringer ingelheim received shares value eur million shares shown investments related companies yearend disclosures contingent liabilities millions eur liabilities guarantees bills cheque guarantees warranties granting security thirdparty liabilities risk utilisation individual contingent liabilities estimated follows risk utilisation guarantees liabilities affiliated companies banks rated low account solid net assets financial position results operations subsidiaries question financial commitments offbalance sheet transactions millions eur rental leasing obligations purchase commitment obligations rental lease agreements eur million previous year eur million eur million previous year eur million relate longterm rental agreements sub sidiaries included consolidation purpose lease agreements lower capital commitment compared buying property absence resale risk risks could arise term lease possible continue utilise properties fully indications time financial commitments include future expenses followup investments investments already initiated future major repairs balance sheet date purchase commitments include future cash flow effects investments totalling eur million previous year eur million product portfolio derivative financial instruments valuation units due extensive international structure boehringer ingelheim group highly dependent devel opments worlds currencies interest rates hedge risks particularly emerging goods services financing currency forwards options generally used currency risks interest rate swaps options used interest rate risks use derivative financial instruments organisational processes set internal guide lines strict separation trading processing documentation control risk positions regularly tracked analysed measured special groupwide financial report positions entered periodically reevaluated monitored fair market values derivative financial instruments calculated using standard market measurement methods currency interest forwards using net present value method currency interest options using recognised option pricing models basis market data available balance sheet date currency interest options recognised fair market value exceeding option premium paid received derecognised maturity provisions eur million recognised currency forwards included hedge accounting negative fair market value within one currency balance sheet date line imparity principle positive fair market values within one currency recognised balance sheet date derivative financial instruments included hedge accounting valuation groups follows nominal value market value millions eur foreign exchange forward contracts extent requirements hedge accounting foreign currency forward exchange contracts highly probable forecasted transactions accordance section hgb met foreign currency forward exchange contracts recognised balance sheet line net hedge presentation method following accounting policies apply recognition hedges accordance section hgb economic hedges accounted financial statements use valuation groups valuation groups recognised foreign currency based net amount highly probable forecasted trans actions currency forwards match forecasted net cash flow terms maturity nominal amount foreign currency macro hedge highly probable forecasted transactions incoming outgoing payments planned sales purchases derived company planning expost analysis planning shown planned transactions highly probable consolidated financial statements notes boehringer ingelheim opposing changes value hedged item hedging instrument fully offset critical terms maturity nominal amount foreign currency match effective hedge therefore assumed prospectively retrospectively critical term match method exclusively used measure pro spective retrospective effectiveness hedges exceeding hedges part valuation group december hedges highly probable forecast net cash flows recognised follows january december net cash flow millions eur fx forward contracts millions eur nominal value nominal value market value usd usd usd jpy jpy jpy aud aud aud mxn mxn mxn cad cad cad gbp gbp gbp january december net cash flow millions eur fx forward contracts millions eur nominal value nominal value market value usd usd usd jpy jpy jpy aud aud aud mxn mxn mxn cad cad cad gbp gbp gbp january december net cash flow millions eur fx forward contracts millions eur nominal value nominal value market value usd usd usd jpy jpy jpy january february net cash flow millions eur fx forward contracts millions eur nominal value nominal value market value jpy jpy jpy product portfolio furthermore december hedges foreign currency receivables recognized follows receivables millions eur forward exchange contracts millions eur nominal value nominal value market value rub rub rub pln pln pln amount hedged foreign currency risk correlates relative change exchange rate planning date realisation date forecast transactions currencies appreciate depreciate euro would foreign currency risk plus minus eur million without hedging part loan agreement raised variable interest rate due july fully redeemed interest rate swaps congruent amount maturity arranged reduce associated risk interest changes expired schedule hedge accounting ended research development expenses millions eur research development expenses noncapitalised research development expenses include amongst items costs associated phase iv clinical studies consolidated financial statements notes boehringer ingelheim report postbalance sheet date events boehringer ingelheim sanofi confirmed successful completion strategic business swap sanofis animal health business merial boehringer ingelheims consumer health care business chc january signing contract june closing carried planned step represents successful completion business exchange begun exclusive negotia tions december researchbased pharmaceutical company boehringer ingelheim improves future market position field animal health significantly establish future one largest global players segment bundling merials boehringer ingelheims complementary product portfo lios well existing technology platforms vaccines antiparasitic pharmaceutical specialty products company placed key growth segments industry offers global customers additional added value innovation expected current sales animal health business going doubled transaction return consumer healt care division given sanofi business unit generated sales eur million within boehringer ingelheim corresponding share around total turnover group fiscal year since end financial year become aware events material significance group companies could lead reappraisal net assets financial position results operations total auditor fees total fees charged group auditor financial year eur million eur million relates audits financial statements eur million assurance services eur mil lion services product portfolio auditors report audited consolidated financial state conducted audit consolidated finan ments prepared ch boehringer sohn ag cial statements accordance article co kg ingelheim comprising balance hgb handelsgesetzbuch german commercial sheet income statement statement changes code german generally accepted standards equity cash flow statement notes audit financial statements promulgated consolidated financial statements together institut der wirtschaftsprfer institute group management report business public auditors germany idw stand year january december ards require plan perform audit preparation consolidated financial state misstatements materially affecting ments group management report presentation net assets financial position accordance german commercial law results operations consolidated responsibility managing directors financial statements accordance german managing corporate general partner responsi principles proper accounting group bility express opinion consolidated management report detected reasonable financial statements group management assurance knowledge business activities report based audit economic legal environment group expectations possible misstate ments taken account determination audit procedures effectiveness accountingrelated internal control system evidence supporting disclosures consoli dated financial statements group manage ment report examined primarily test basis within framework audit audit includes assessing annual financial statements companies included consolidation determination companies included consolidation accounting consolidation principles used significant estimates made managing directors managing corporate general partner well evaluating overall presentation consolidated financial state ments group management report believe audit provides reasonable basis opinion consolidated financial statements notes boehringer ingelheim exception following qualification audit led reservations contrary article nos b hgb total remuneration granted members former members board managing direc tors members supervisory body well pension provisions recognized recognized former members board managing directors disclosed notes consolidated financial statements opinion based findings audit qualification mentioned con solidated financial statements comply legal requirements give true fair view net assets financial position results operations group accordance ger man principles proper accounting group management report consistent consoli dated financial statements complies legal requirements whole provides suitable view groups position suitably presents opportunities risks future development frankfurt main march pricewaterhousecoopers gmbh wirtschaftsprfungsgesellschaft dr ulrich strk michael conrad wirtschaftsprfer wirtschaftsprfer german certified german certified public accountant public accountant product portfolio p r u c p r f l e l e c n prescription medicines animal health animal health product overview based portfolio strate gic business swap boehringer ingelheim sanofi finalised boehringer ingelheims consumer healthcare business chc transferred sanofi boehringer ingelheim acquired sanofis animal health business merial merial portfolio reflected overview product portfolio prescription medicines boehringer ingelheim respiratory diseases respiratory diseases common chronic obstructive bronchial asthma pulmonary disease copd bronchial asthma bronchial asthma chronic inflammatory disorder among prevalent chronic diseases frequent airways inflammation accompanied airway cause morbidity premature deaths worldwide hyperresponsiveness leads narrowing airways recurrent episodes wheezing breathless idiopathic pulmonary fibrosis ipf rare disease ness coughing symptoms occur particularly severely debilitating ultimately lethal night early hours morning known asthma triggered genetic envi copd ronmental factors eg allergens viral infections copd chronic disease lungs causes cough unlike copd asthma occur early childhood ing excessive mucus production inflammation also present adolescents adults asthma ultimately destroys lung tissue alveoli thus gas often underestimated easytomanage condition exchange affected leads limitation however almost one two patients asthma still airflow causing shortness breath respira experience symptoms receiving maintenance ther tory symptoms airflow limitation partially apy putting increased risk potentially reversible usually worsens time leading disa lifethreatening asthma exacerbations bility ultimately death symptoms excess cough breathlessness main reasons copd stressful patients lung emphysema chronic bronchitis main manifestations copd copd caused continuous damage lungs result ing inhaling pollutants primarily cigarette smoke however factors also need considered includ ing indoor outdoor air pollution course copd disease occurs second half humans life characterised accelerated loss lung function compared normal ageing occasional sudden worsening symptoms f unction referred acute exacerbations lead downward spiral worsening symptoms thus fur ther inactivity indications brand names active ingredients chronic obstructive spiriva tiotropium bromide maintenance treatment patients pulmonary disease copd spiriva handihaler copd including chronic bronchitis spiriva respimat emphysema maintenance treatment associated dyspnoea prevention exacerbations bronchial asthma spiriva respimat tiotropium bromide addon maintenance treatment adult patients asthma currently treated maintenance combination inhaled corticosteroids spiriva respimat approved use asthma eu japan usa many countries label varies country please refer local product information chronic obstructive spiolto respimat tiotropium bromide maintenance treatment airflow pulmonary disease copd stiolto respimat olodaterol obstruction patients chronic inspiolto respimat hydrochloride obstructive pulmonary disease copd chronic obstructive striverdi respimat olodaterol maintenance treatment patients pulmonary disease copd hyrochloride chronic obstructive pulmonary disease copd reversible bronchospasms combivent respimat ipratropium bromide combination shortacting associated obstructive salbutamol sulphate anticholinergic betaadrenergic airway diseases management reversible broncho spasms associated obstructive airway diseases patients requiring one bronchodilator chronic obstructive atrovent ipratropium bromide prevention treatment shortness pulmonary disease copd breath patients chronic chronic bronchitis obstructive pulmonary disease copd bronchial asthma mild moderate bronchial asthma adulthood childhood supple ment betaagonists cases acute asthma chronic obstructive airway berodual ipratropium bromide fenoterol prevention treatment symptoms disorders bronchodual hydrobromide chronic obstructive airway disorders duovent reversible airflow limitation bronchial asthma especially chronic bronchitis without emphysema product portfolio prescription medicines boehringer ingelheim respiratory diseases continued idiopathic pulmonary fibrosis ipf acute ipf exacerbations defined rapid deteriorations ipf progressive lung disease associated markedly symptoms lung function within days weeks reduced life span affecting many people events occur point course disease per worldwide ipf characterised progressive even first presentation associated high mor scarring lung tissue loss lung function tality patients ipf risk acute ipf exacer time development scarred tissue called fibrosis bations time tissue thickens stiffens scarring lungs lose ability take transfer oxygen bloods tream vital organs get enough oxy gen result individuals ipf experience shortness breath even resting often difficulty participating everyday physical activities indications brand names active ingredients bronchial asthma berotec fenoterol hydrobromide symptomatic treatment acute asthma attacks prophylaxis exerciseinduced asthma bronchiale symptomatic treatment allergic nonallergic asthma bronchiale conditions reversible airway narrowing eg chronic obstructive bronchitis bronchial asthma alesion epinastine hydrochloride prophylactic treatment patients allergic rhinitis flurinol bronchial asthma prophylaxis symp tomatic treatment allergic rhinitis idiopathic pulmonary fibrosis ofev nintedanib esylate treatment patients idiopathic ipf pulmonary fibrosis ipf product portfolio prescription medicines boehringer ingelheim cardiovascular metabolic diseases cardiovascular cv disease leading cause death prevention treatment venous many countries still increasing prevalence thromboembolism currently responsible nearly one three deaths venous thromboembolism vte umbrella term worldwide one key risk factor developing cardio encompasses deep vein thrombosis dvt pulmonary vascular disease presence diabetes people embolism pe dvt process occurs diabetes two four times likely develop thrombus blood clot forms deep vein commonly cardiovascular disease people without diabetes calf leg partially completely blocks result life expectancy years shorter flow blood thrombus grows portion may proper control diabetes treatable risk factors break away main clot travel circulatory therefore vital prevention cardiovascular events system lungs lodging blood clot arteries lung called pe vte serious disor stroke der potentially fatal consequences stroke rapidly developing loss brain functions caused reduced blood flow affected brain tis patients undergoing orthopaedic surgery considerable sue due ischaemia lack blood supply risk developing vte chronic venous insufficiency caused thrombosis embolism due bleeding andor pulmonary hypertension may develop longer result affected area brain unable term prevent vte events consequences function damage quickly becomes permanent orthopaedic surgery patients receive kind untreated stroke acute event requiring emergency thromboprophylaxis patients already suffered diagnosis intervention worldwide stroke one vte require anticoagulant treatment secondary leading causes death longterm disability prevention recurrent thromboembolic event symptoms transient ischaemic attack tia similar stroke last minutes hours reversing anticoagulation usually result permanent neurological damage anticoagulants offer important benefits patients risk tia may precede stroke emergency medical care thromboembolic events however even though rare subsequent preventive treatment may necessary situations rapid reversal anticoagu lation could medically necessary eg patient taking atrial fibrillation anticoagulant involved severe car accident atrial fibrillation af common sustained needs emergency surgery heart rhythm condition affecting approximately two per cent total population one four adults develops arrhythmia lifetime patients af higher risk developing blood clots upper left heart chamber cause disabling stroke clot breaks loose travels brain af leads fivefold increase risk stroke result ing three million patients worldwide suffering afrelated strokes year risk stroke reduced effective chronic anticoagulation indications brand names active ingredients stroke prevention atrial pradaxa dabigatran etexilate prevention strokes blood clots fibrillation pradaxar patients abnormal heart rhythm primary prevention venous prazaxa atrial fibrillation thromboembolic events orthopaedic surgery primary prevention venous thrombo treatment secondary embolic events vte adults prevention venous throm elective total hip knee replacement boembolic events surgery treatment deep vein thrombosis dvt pulmonary embolism pe secondary prevention recurrent dvt pe adults specific reversal pradaxa praxbind idarucizumab praxbind specific reversal agent dabigatran etexilate dabigatran indicated adult patients treated pradaxa dab igatran etexilate rapid reversal anticoaculant effects required emergency surgeryurgent procedures lifethreatening uncontrolled bleeding hypertension micardis telmisartan treatment hypertension cardiovascular morbidity micardisplus telmisartan hydrochlorothiazide reduction risk myocardial mortality prevention micardis plus infarction heart attack stroke death cardiovascular cv causes micardishct patients years age older high comicardis risk developing major cv events unable take ace inhibitors usa reduction cardiovascular morbidity patients manifest atherothrombotic cardiovascular disease history coronary heart disease stroke peripheral arterial disease patients type diabetes mellitus documented target organ damage eu h ypertension twynsta telmisartan amlodipine treatment hypertension alone micamlo antihypertensive agents initial micardis amlo therapy patients likely need multi ple antihypertensive agents achieve micardis duo blood pressure goals usa addon therapy adult patients adequately controlled blood pres sure amlodipine replacement therapy adult patients receiving tel misartan amlodipine separate tablets eu product portfolio prescription medicines boehringer ingelheim cardiovascular metabolic diseases continued hypertension cardiovascular diseases hypertension also referred high blood pressure chronic disease blood pressure chronically elevated hypertension also one major risk factors stroke heart attacks heart failure chronic renal failure primary goal antihypertensive treatment prevent cardiovascular events reduce cardiovascular mortality acute myocardial infarction acute myocardial infarction heart attack event occurs thrombus clot suddenly pre vents blood flow area heart muscle unless blood flow restored quickly affected section heart muscle becomes permanently damaged heart attack leading cause death developed countries indications brand names active ingredients acute ischaemic stroke actilyse alteplase fibrinolytic treatment acute ischae acute myocardial infarction actilyse cathflo mic stroke acute myocardial infarction acute massive pulmonary acute massive pulmonary embolism embolism fibrinolytic treatment occluded catheter clearance due catheters thrombotic occlusion secondary prevention aggrenox dipyridamole prevention stroke following initial stroke transient ischaemic asasantin acetylsalicylic acid first stroke transient ischaemic attacks tia asasantin retard attacks tia acute myocardial infarction metalyse tenecteplase fibrinolytic treatment acute myocar dial infarction hypertension catapresan clonidine treatment hypertension catapres hydrochloride clonidine catapressan cataprestts hypertension motens lacidipine treatment hypertension product portfolio prescription medicines boehringer ingelheim cardiovascular metabolic diseases continued diabetes approximately per cent deaths people type type diabetes chronic progressive condition associated diabetes caused cardiovascular disease indicating elevated blood sugar levels cause longterm high unmet medical need complications treated addition cardiovascular disease serious complications every year million deaths worldwide linked directly diabetes include nephropathy leading renal failure longterm effects diabetes type diabetes potentially dialysis retinopathy potential loss common form diabetes accounts vision peripheral neuropathy risk foot ulcers cases developed world affects mil foot leg amputations autonomic neuropathy caus lion people worldwide imposing enormous burden ing gastrointestinal genitourinary cardiovascular health care systems globally without effective preven symptoms sexual dysfunction tion management strategies estimated number cases reach million type diabetes one major risk factors cardio vascular disease life expectancy people type dia betes high cardiovascular risk average decreased twelve years indications brand names active ingredients type diabetes mellitus trajenta linagliptin treatment type diabetes mellitus tradjenta improve glycaemic control adults trazenta used monotherapy metformin tolerated contraindicated trayenta combination therapy type diabetes mellitus jentadueto linagliptin metformin hydrochloride treatment type diabetes mellitus trayenta duo improve glycaemic control adults trajenta duo treatment metformin lead sufficient control trajentamet patients treated trajenta linagliptin metformin type diabetes mellitus jardiance empagliflozin treatment adults type diabetes jardianz mellitus adjunct diet exer cise improve glycemic control reduce risk cardiovascular death patients established cardiovas cular disease type diabetes mellitus synjardy empagliflozin treatment type diabetes mellitus metformin improve glycaemic control adults hydrochloride treatment metformin lead sufficient control patients treated jardiance empagliflozin metformin type diabetes mellitus glyxambi empagliflozin linagliptin treatment type diabetes mellitus improve glycaemic control adults treatment empagliflozin linagliptin appropriate us iabetes portfolio collaboration eli lilly company product portfolio prescription medicines boehringer ingelheim oncology cancer threat global health estimated disease may take many years appear late diag million new cases cancer diagnosed world nosis advanced stage disease results wide million people died cancer stewart often dismal prognosis lung cancer world cancer report common diagnosed patients surviving five years following diagnosis cancer types lung cancer nearly breast cancer almost colorectal cancer approx lung cancer one disease dif ferent subtypes small cell lung cancer sclc lung cancer nonsmall cell lung cancer nsclc differ lung cancer refers malignant abnormal cell growth ent molecular genetic aberrations mutations present inside lung tissue forming cluster tumour tumour identified focusing molecular common cancer estimated million new changes specific respective subtype lung cases per year worldwide smoking primary cancer targeted therapies become effective cause disease contributing nearly treatments show survival benefit cases recently however incidence lung cancer among time less harmful normal cells thereby nonsmokers increased lung cancer poor prog reducing side effects nosis million deaths per year representing cancer deaths lung cancer symptoms unspecific indications brand names active ingredients nonsmall cell lung cancer giotrif afatinib treatment patients meta nsclc gilotrif static nonsmall cell lung cancer nsclc whose tumours activating epidermal growth factor receptor egfr mutations treatment patients locally advanced metastatic nsclc squamous histology progress ing platinum based chemo therapy nonsmall cell lung cancer vargatef nintedanib combination therapy docetaxel nsclc treatment adult patients locally advanced metastatic locally nonsmall cell lung cancer nsclc adenocarcinoma tumour histology firstline chemotherapy product portfolio prescription medicines boehringer ingelheim diseases central nervous system mental neurological diseases depression dementia depression sleep disorders primary parkinsons disease significantly impact patients symptoms result lack neurotransmitter families also substantial burden society dopamine distinct areas human brain parkinsons disease restless legs syndrome rls parkinsons disease pd degenerative disorder restless legs syndrome rls common neurological central nervous system patients usually notice motor disorder characterised uncontrollable urge move symptoms like hand tremor shaking first sign legs primarily occurring evening night disease may progress include shaking hours usually accompanied unpleasant arms legs head motor symptoms may times painful sensations legs well disturbed develop time include stiffness often results sleep resulting daytime tiredness sleepiness loss facial expression gradual slowing loss sensations felt deep within legs described motion freezing patients also suf creeping crawling aching fer nonmotor symptoms associated pd infectious diseases hiv infectionaids acquired immune deficiency syndrome aids set symptoms infections resulting damage human immune system caused human immu nodeficiency virus hiv untreated infection hiv progressively reduces effectiveness immune system leaves individuals susceptible opportunistic infections tumours babies infected mothers risk getting virus pregnancy childbirth breastfeeding indications brand names active ingredients parkinsons disease pd sifrol pramipexole symptomatic treatment idiopathic restless legs syndrome rls mirapex parkinsons disease may used mirapexin monotherapy combination levodopa symptomatic treatment pexola idiopathic moderate severe restless legs syndrome sleep disorders lendormin brotizolam shortterm treatment disorders initiating maintaining sleep insomnia requiring pharmacological intervention indications brand names active ingredients hivaids viramune nevirapine combination therapy hiv viramune xr infection several countries prevention mothertochild trans mission hiv pregnant women taking antiretroviral therapy time labour prolonged release tablets oncedaily dosing within combination therapy hivaids aptivus tipranavir indicated combination antiretroviral treatment hivinfected patients coadministered mg ritona vir treatmentexperienced infected hiv strains resistant one protease inhibitor product portfolio animal health boehringer ingelheim reference animal health product overview based port chc transferred sanofi boehringer ingelheim folio strategic business acquired sanofis animal health business merial swap boehringer ingelheim sanofi final merial portfolio reflected overview ised boehringer ingelheims consumer healthcare business livestock swine infectious respiratory diseases infectious enteric diseases ingelvac circoflex first singledose piglet vaccine enterisol ileitis first vaccine control porcine circovirus disease pcvd ileitis caused lawsonia intracellularis licensed vaccine provides significant reduction mortality improve weight gain reduce growth variability acute phase pcvd well improved growth rates associated disease enterisol ileitis helps chronic phase disease ingelvac circoflex reduce total antimicrobial use pork production protects minimal systemic adverse reactions injec tion site swellings used pregnancy lactation ingelvac prrs products licensed active immunisation respiratory reproductive form porcine reproductive respiratory syndrome prrs ingelvac mycoflex licensed active immunisa tion pigs enzootic pneumonia ep single dose regimen advanced adjuvant system provides longlasting effective protection proven even highchallenge situations livestock poultry volvac umbrella brand boehringer ingelheim various viral bacterial diseases like avian influenza animal health poultry vaccine range consists wide infectious bronchitis newcastle disease infectious bursal range live inactivated vaccines broilers lay disease egg drop syndrome avian coryza ers vaccines provide protection birds indications brand names active ingredients infectious respiratory ingelvac circoflex recombinant vaccine active immunisation pigs iseases porcine circovirus age two weeks porcine type pcv circovirus type reduce mortality clinical signs including weight loss lesions lymphoid tissues asso ciated porcine circovirus diseases pcvd addition vaccination shown reduce pcv nasal shed ding viral load blood lymphoid tissues duration viraemia infectious respiratory ingelvac prrs mlv attenuated live vaccine prrs virus depending product active iseases ingelvac prrsflex eu type prrs mlv immunisation pigs various ages reprocyc type prrsflex eu porcine reproductive reprocyc respiratory syndrome virus prrsv infectious respiratory ingelvac mycoflex inactivated vaccine active immunisation pigs iseases mycoplasma age three weeks reduce lung hyopneumoniae lesions following infections myco plasma hyopneumoniae infectious enteric diseases enterisol ileitis attenuated live vaccine lawsonia active immunisation pigs intracellularis age three weeks intestinal lesions caused lawsonia intracellula ris infection reduce growth varia bility loss weight gain associated disease indications brand names active ingredients various viral bacterial volvac polyvalent attenuated live vaccination healthy chickens diseases poultry inactivated vaccine diseases caused containing antigens included antigens prevention vaccination avian common diseases broiler influenza newcastle chickens diseases responsible disease avian coryza egg losses egg production layers drop syndrome infectious bronchitis infectious bursal disease bacterium anatis product portfolio animal health boehringer ingelheim livestock cattle mastitis mastitis inflammation udder dairy cattle mainly caused bacterial infection prevention treatment mastitis animals key producing healthy milk minimising symptoms associated clinical situation mamyzin effective injectable antimicrobial treatment acute masti tis ubrolexin today two products treatment acute bacterial mastitis whereas ubrostar tomorrow used prevent mastitis dry ingoff dairy cattle end lactation period indications brand names active ingredients astitis mamyzin penethamate hydroiodide bovine mastitis caused penicillin sensitive organisms astitis ubrostar penethamate hydroiodide framyce treatment subclinical mastitis benestermycin tin sulphate benethamine penicillin dryingoff prevention new mamyzin secado bacterial infections udder dry period dairy cows caused bacteria susceptible penicillin framycetin astitis ubrolexin cefalexin kanamycin combination treatment clinical mastitis lactating dairy cows bacteria susceptible combination cefalexin kana mycin astitis today cephapirin sodium treatment clinical mastitis lactating cefalak dairy cows uscanada astitis tomorrow cephapirin benzathine treatment subclinical mastitis cefadri dryingoff prevention new bacterial infections udder dry period dairy cows uscan ada intramammary infusion dry cow us product portfolio animal health boehringer ingelheim livestock cattle continued pain inflammatory disorders infectious diseases metacam nonsteroidal antiinflammatory drug pyramid family vaccines providing broad nsaid addresses need maintained profita coverage respiratory reproductive diseases bility concern animal welfare animal pro range consists several antigen combinations duction due longacting nature outstand ing efficacy controlling inflammatory symptoms bovine viral diarrhoea virus bvdv one major metacam helps minimise losses inflammation economically relevant cattle pathogens maintain profitability time metacam worldwide distribution disease caused bvdv effectively controls pain supports restoration results marked production losses dairy beef wellbeing farm animals use metacam herds bovela vaccine designed reduce convenient inflicts minimal stress animals due clinical signs typical bvd prevent lowvolume oneshot dosage birth socalled persistently infected animals caused transplacental infection bvdv vaccina metacam licensed adjunctive therapy treat tion bovela expected provide protection ment mastitis lactating cows countries within herd disease cir also indicated use calves affected diarrhoea culation virus cattle suffering respiratory disease indications brand names active ingredients pain inflammatory metacam meloxicam cattle metacam used together isorders appropriate antibiotic therapy reduce clinical signs disease acute respiratory infection used diarrhoea combination oral rehydration therapy reduce clinical signs disease calves one week age young nonlactating cattle also used relief postoperative pain following dehorning calves supportive therapy treatment acute mastitis com bination antibiotics cattle infectious diseases pyramid several multivalent vaccine combina vaccination healthy dairy beef respiratory reproductive presponse tions including modified live viruses cattle aid prevention diseases diseases cattle bovine viral diarrhoea bvd types caused included antigens us infectious bovine rhinotrache canada itis ibr parainfluenza pi bovine respiratory syncytial virus brsv bacteria pasteurella multocida mannheimia haemolyt ica l canicola l grippotyphosa l hardjo l icterohaemmorrhagiae l pomona bovine viral diarrhoea bvd bovela modified live bvdv strain bovela used protect cattle modified live bvdv strain bvd viral infection bovine viral diarrhoea virus product portfolio animal health boehringer ingelheim companion animals horse main horse products focus therapeutic areas vetera vaccines formulated utilising ultrafil respiratory disease lameness colic hormonal dis purification technology removing extraneous pro orders teins allowing horses immune system focus relevant antigens prascend indicated treatment pituitary pars intermedia dysfunction ppid also known respiratory segment two products available global equine cushings disease prascend substitutes level ventipulmin equisolon products lack dopamine pituitary pars intermedia clinical licensed treatment respiratory disease including airway signs hypertrichiosis laminitis change body con obstruction horses wheeze cough difficulty formation lack performance treatment pras breathing due bronchospasm andor mucus accumulation cend lifelong ventipulmin equisolon used alone adjunctive therapy chronic obstructive pulmonary disease vetera vaccines first vaccine portfolio copd acute subacute chronic respiratory allergic include multiple convenient combinations disease pro conditions tection horses young four months age vaccines protect many nine infectious organisms including influenza herpes west nile virus tetanus others enables customised protec tion horse limited needle injections indications brand names active ingredients pituitary pars intermedia prascend pergolide mesylate symptomatic treatment clinical signs dysfunction ppid associated pituitary pars intermedia dysfunction ppid also known equine cushings disease combination vaccine vetera eastern western venezuelan vaccination healthy horses nine common diseases encephalomyelitis tetanus west aid prevention diseases caused horses nile virus equine included antigens us herpes virus equine ada influenza viruses acute chronic obstructive ventipulmin clenbuterol treatment respiratory disease horses respiratory diseases airway obstruction due bron chospasm andor accumulation mucus improved mucociliary clear ance desirable recurrent airway obstruction equisolon prednisolone treatment recurrent airway rao heaves obstruction rao heaves horses combination environmental measures product portfolio animal health boehringer ingelheim companion animals small animals main small animal products address major chronic prozinc aqueous protamine zinc pzi suspension diseases heart failure kidney diseases epilepsy recombinant human insulin used reduce osteoarthritis hyperglycaemia cats diabetes mellitus first new class heart treatments termed semintra angiotensin ii antagonist inodilators vetmedin shown significantly approved reduction proteinuria associated improve clinical signs extend life expectancy dogs chronic kidney disease ckd cats semintra congestive heart failure originating dilated decreases mean arterial blood pressure proteinuria cardiomyopathy valvular insufficiency mitral andor available oral solution tricuspid regurgitation vetmedin works two complementary modes action opens blood pexion alternative treatment canine epilepsy vessels taking blood away heart thereby active substance imepitoin primarily inhibits sei lowering pressure heart reducing zures via potentiation gabaareceptormediated work heart pump blood around dogs inhibitory effects neurons pexion approved body time vetmedin direct effect reduction generalised seizures due idiopathic epi heart muscle helping beat stronger pump lepsy potential safety benefits existing blood efficiently standard treatment metacam nonsteroidal antiinflammatory drug nsaid available oral suspension tablets injectable solution dogs oral suspen sion injectable solution cats dogs indica tions include alleviation inflammation pain acute chronic musculoskeletal disorders well reduction pain following surgery cats indications include alleviation inflammation pain acute chronic musculoskeletal disor ders well alleviation mild moderate post operative pain variety formulations offers veteri narians owners flexibility use formulation prefer individual cases manage various levels inflammation pain associated licensed indications indications brand names active ingredients congestive heart failure vetmedin pimobendan treatment canine congestive heart failure originating dilatative cardio myopathy valvular insufficiency mitral andor tricuspid regurgitation treatment dilated cardiomyopa thy preclinical stage asymptomatic increase left ventricular endsystolic enddiastolic diameter doberman pinschers following echo cardiographic diagnosis cardiac disease pain inflammatory metacam meloxicam dogs metacam used reduce diseases postoperative pain inflammation following orthopaedic eg fracture oper ation soft tissue surgery cats metacam used reduce postoperative pain inflammation ovariohysterectomy spay opera tion orthopaedic minor soft tissue surgery moreover used alleviation pain inflammation acute chronic musculoskeletal disorders dogs cats feline diabetes mellitus prozinc protamine zinc reduction hyperglycaemia recombinant hyperglycaemiaassociated clinical signs human insulin cats diabetes mellitus feline chronic kidney disease semintra telmisartan reduction proteinuria associated chronic kidney disease ckd cats canine idiopathic epilepsy pexion imepitoin reduction frequency generalised seizures due idiopathic epilepsy dogs careful evaluation alternative treatment options comparison balance sheets boehringer ingelheim c h boehringer sohn ag co kg ingelheim comparison balance sheets millions eur assets december intangible assets tangible assets financial assets fixed assets inventories accounts receivable incl deferred charges deferred taxes liquid funds current assets incl deferred charges deferred taxes total assets liabilities equity december shareholders capital group reserves incl currency conversion difference group profit equity attributable parent company noncontrolling interests group equity difference capital consolidation provisions incl deferred taxes liabilities incl deferred charges total liabilities incl deferred taxes deferred charges total liabilities equity summary selected financial data net sales operating income operating income net sales income taxes income taxes net sales return equity equity ratio cash flow financial funds personnel expenses personnel expenses net sales average number employees research development costs rd net sales investments tangible assets depreciation tangible assets imprint assets december intangible assets tangible assets financial assets boehringer ingelheim gmbh binger strae fixed assets ingelheim inventories germany accounts receivable incl deferred charges deferred taxes telephone fax liquid funds current assets incl deferred charges deferred taxes contact total assets corporate division communications public affairs email pressboehringeringelheimcom internet wwwboehringeringelheimcom liabilities equity december shareholders capital issued group reserves incl currency conversion difference boehringer ingelheim gmbh group profit concept design layout equity attributable parent company mpm corporate communication solutions mainz noncontrolling interests wwwmpmde group equity difference capital consolidation photos provisions incl deferred taxes dieth schrder fotografie p liabilities incl deferred charges printed total liabilities incl deferred taxes deferred charges neue sddeutsche verlagsdruckerei gmbh ulm total liabilities equity copyright boehringer ingelheim gmbh summary selected financial data rights reserved part annual report may net sales reproduced transmitted form means operating income electronic photocopy without permission writing boehringer ingelheim gmbh figures third parties used operating income net sales annual report based data available time income taxes financial statement drawn income taxes net sales return equity equity ratio cash flow financial funds personnel expenses personnel expenses net sales average number employees research development costs rd net sales investments tangible assets depreciation tangible assets wwwboehringeringelheimcom annualreportboehringeringelheimcom